voclosporin (Rx)

Lupus Nephritis

Indicated in combination with a background immunosuppressive therapy regimen for active lupus nephritis (LN)

23.7 mg PO BID initially; modify dose based on eGFR

Use in combination with mycophenolate mofetil (MMF) and corticosteroids

Consider discontinuation if no therapeutic benefit by 24 weeks

Safety and efficacy not established >1 year; consider risks and benefits of longer durations of treatment in light of treatment response and risk of nephrotoxicity

Dosage Modifications

eGFR dosage adjustments

• If eGFR <60 mL/min/1.73 m² and reduced from baseline by >20 to <30%: Reduce by 7.9 mg BID; reassess within 2 weeks; if eGFR is still reduced from baseline by >20%, reduce dose again by 7.9 mg BID
• If eGFR <60 mL/min/1.73 m² and reduced from baseline by ≥30%: Discontinue; reassess within 2 weeks; consider restarting at lower dose (eg, 7.9 mg BID) only if eGFR returns to ≥80% of baseline
• Dose reductions due to eGFR: Consider increasing dose by 7.9 mg BID for each eGFR ≥80% of baseline; do not exceed starting dose

Coadministration of CYP3A4 inhibitors/inducers

• Strong CYP3A4 inhibitors: Contraindicated
• Moderate CYP3A4 inhibitors: Reduce voclosporin to 15.8 mg qAM and 7.9 mg qPM
• Mild CYP3A4 inhibitors: No dosage adjustment necessary
• Strong CYP3A4 inducers: Avoid coadministration
• Avoid any food or drink containing grapefruit

Renal impairment

• Baseline eGFR ≤45 mL/min/1.73 m²: Use not recommended unless benefits outweigh risks; not studied If used in patients with severe renal impairment (eGFR <30 mL/min/1.73 m²) at baseline: Decrease starting dose to 15.8 mg PO BID
• End-stage renal disease with or without hemodialysis: Pharmacokinetics are unknown

Hepatic impairment

• Mild or moderate (Child-Pugh A or B): Reduce to 15.8 mg BID
• Severe (Child-Pugh C): Not recommended

Dosing Considerations

Monitoring parameters

• Before initiating therapy

  • Baseline parameters: eGFR and blood pressure (BP)
  • Use not recommended in patients with a baseline eGFR ≤45 mL/min/1.73 m2 unless benefits outweigh risks
  • Do not initiate in if BP >165/105 mmHg or with hypertensive emergency

• During treatment

  • eGFR: Every 2 weeks for first month, and every 4 weeks thereafter
  • BP: Every 2 weeks for first month, and as clinically indicated thereafter

Limitation of use

• Safety and efficacy not established in combination with cyclophosphamide; use not recommended

Safety and efficacy not established

Contraindicated (29)

• abametapir

  abametapir will increase the level or effect of voclosporin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated.

• atazanavir

  atazanavir will increase the level or effect of voclosporin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated.

• ceritinib

  ceritinib and voclosporin both increase QTc interval. Contraindicated.

• chloramphenicol

  chloramphenicol will increase the level or effect of voclosporin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated.

• clarithromycin

  clarithromycin will increase the level or effect of voclosporin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated.

• cobicistat

  cobicistat will increase the level or effect of voclosporin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated.

• conivaptan

  conivaptan will increase the level or effect of voclosporin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated.

• darunavir

  darunavir will increase the level or effect of voclosporin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated.

• elvitegravir/cobicistat/emtricitabine/tenofovir DF

  elvitegravir/cobicistat/emtricitabine/tenofovir DF will increase the level or effect of voclosporin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated.

• grapefruit

  grapefruit will increase the level or effect of voclosporin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated.

• idelalisib

  idelalisib will increase the level or effect of voclosporin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated.

• indinavir

  indinavir will increase the level or effect of voclosporin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated.

• isoniazid

  isoniazid will increase the level or effect of voclosporin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated.

• itraconazole

  itraconazole will increase the level or effect of voclosporin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated.
  
  itraconazole and voclosporin both increase QTc interval. Contraindicated.

• ketoconazole

  ketoconazole will increase the level or effect of voclosporin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated.

• levoketoconazole

  levoketoconazole will increase the level or effect of voclosporin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated.

• lonafarnib

  lonafarnib will increase the level or effect of voclosporin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated.

• lopinavir

  lopinavir will increase the level or effect of voclosporin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated.

• mifepristone

  mifepristone will increase the level or effect of voclosporin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated.

• nefazodone

  nefazodone will increase the level or effect of voclosporin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated.

• nelfinavir

  nelfinavir will increase the level or effect of voclosporin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated.

• nirmatrelvir/ritonavir

  nirmatrelvir/ritonavir will increase the level or effect of voclosporin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Nirmatrelvir/ritonavir is contraindicated with drugs that are highly dependent on CYP3A for clearance and for which elevated concentrations are associated with serious and/or life-threatening reactions. May increase risk of acute and/or chronic nephrotoxicity associated with voclosporin.

• posaconazole

  posaconazole will increase the level or effect of voclosporin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated.

• ritonavir

  ritonavir will increase the level or effect of voclosporin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated.

• rucaparib

  rucaparib will increase the level or effect of voclosporin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated.

• saquinavir

  saquinavir will increase the level or effect of voclosporin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated.

• stiripentol

  stiripentol will increase the level or effect of voclosporin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated.

• tipranavir

  tipranavir will increase the level or effect of voclosporin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated.

• voriconazole

  voriconazole will increase the level or effect of voclosporin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated.

Serious - Use Alternative (73)

• adenovirus types 4 and 7 live, oral

  voclosporin decreases effects of adenovirus types 4 and 7 live, oral by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Immunosuppressants also increase risk of infection with concomitant live vaccines. Avoid live vaccines for at least 3 months after immunosuppressants.

• amisulpride

  amisulpride and voclosporin both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.

• amobarbital

  amobarbital will decrease the level or effect of voclosporin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.

• anagrelide

  anagrelide and voclosporin both increase QTc interval. Avoid or Use Alternate Drug.

• apalutamide

  apalutamide will decrease the level or effect of voclosporin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.

• armodafinil

  armodafinil will decrease the level or effect of voclosporin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.

• artemether

  artemether and voclosporin both increase QTc interval. Avoid or Use Alternate Drug.

• axicabtagene ciloleucel

  voclosporin, axicabtagene ciloleucel. Either increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug.

• BCG vaccine live

  voclosporin decreases effects of BCG vaccine live by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Immunosuppressants also increase risk of infection with concomitant live vaccines. Avoid live vaccines for at least 3 months after immunosuppressants.

• bexarotene

  bexarotene will decrease the level or effect of voclosporin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.

• bosentan

  bosentan will decrease the level or effect of voclosporin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.

• brexucabtagene autoleucel

  voclosporin, brexucabtagene autoleucel. Either increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug.

• brigatinib

  brigatinib will decrease the level or effect of voclosporin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.

• buprenorphine

  buprenorphine and voclosporin both increase QTc interval. Avoid or Use Alternate Drug.

• buprenorphine buccal

  buprenorphine buccal and voclosporin both increase QTc interval. Avoid or Use Alternate Drug.

• buprenorphine subdermal implant

  buprenorphine subdermal implant and voclosporin both increase QTc interval. Avoid or Use Alternate Drug.

• buprenorphine transdermal

  buprenorphine transdermal and voclosporin both increase QTc interval. Avoid or Use Alternate Drug.

• buprenorphine, long-acting injection

  buprenorphine, long-acting injection and voclosporin both increase QTc interval. Avoid or Use Alternate Drug.

• butabarbital

  butabarbital will decrease the level or effect of voclosporin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.

• butalbital

  butalbital will decrease the level or effect of voclosporin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.

• carbamazepine

  carbamazepine will decrease the level or effect of voclosporin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.

• chloroquine

  chloroquine and voclosporin both increase QTc interval. Avoid or Use Alternate Drug.

• cholera vaccine

  voclosporin decreases effects of cholera vaccine by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Immunosuppressants also increase risk of infection with concomitant live vaccines. Avoid live vaccines for at least 3 months after immunosuppressants.

• ciltacabtagene autoleucel

  voclosporin, ciltacabtagene autoleucel. Either increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug.

• clobazam

  clobazam will decrease the level or effect of voclosporin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.

• dabrafenib

  dabrafenib will decrease the level or effect of voclosporin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.

• dengue vaccine

  voclosporin decreases effects of dengue vaccine by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Immunosuppressants also increase risk of infection with concomitant live vaccines. Avoid live vaccines for at least 3 months after immunosuppressants.

• desflurane

  desflurane and voclosporin both increase QTc interval. Avoid or Use Alternate Drug.

• Ebola Zaire vaccine

  voclosporin decreases effects of Ebola Zaire vaccine by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Immunosuppressants also increase risk of infection with concomitant live vaccines. Avoid live vaccines for at least 3 months after immunosuppressants.

• efavirenz

  efavirenz will decrease the level or effect of voclosporin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.
  
  efavirenz and voclosporin both increase QTc interval. Avoid or Use Alternate Drug.

• elagolix

  elagolix will decrease the level or effect of voclosporin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.

• encorafenib

  encorafenib will decrease the level or effect of voclosporin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.

• enzalutamide

  enzalutamide will decrease the level or effect of voclosporin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.

• eslicarbazepine acetate

  eslicarbazepine acetate will decrease the level or effect of voclosporin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.

• etravirine

  etravirine will decrease the level or effect of voclosporin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.

• idecabtagene vicleucel

  voclosporin, idecabtagene vicleucel. Either increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug.

• influenza virus vaccine quadrivalent, intranasal

  voclosporin decreases effects of influenza virus vaccine quadrivalent, intranasal by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Immunosuppressants also increase risk of infection with concomitant live vaccines. Avoid live vaccines for at least 3 months after immunosuppressants.

• isoflurane

  isoflurane and voclosporin both increase QTc interval. Avoid or Use Alternate Drug.

• ivosidenib

  ivosidenib will decrease the level or effect of voclosporin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.

• lisocabtagene maraleucel

  voclosporin, lisocabtagene maraleucel. Either increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug.

• lorlatinib

  lorlatinib will decrease the level or effect of voclosporin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.

• lumacaftor/ivacaftor

  lumacaftor/ivacaftor will decrease the level or effect of voclosporin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.

• measles (rubeola) vaccine

  voclosporin decreases effects of measles (rubeola) vaccine by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Immunosuppressants also increase risk of infection with concomitant live vaccines. Avoid live vaccines for at least 3 months after immunosuppressants.

• measles mumps and rubella vaccine, live

  voclosporin decreases effects of measles mumps and rubella vaccine, live by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Immunosuppressants also increase risk of infection with concomitant live vaccines. Avoid live vaccines for at least 3 months after immunosuppressants.

• measles, mumps, rubella and varicella vaccine, live

  voclosporin decreases effects of measles, mumps, rubella and varicella vaccine, live by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Immunosuppressants also increase risk of infection with concomitant live vaccines. Avoid live vaccines for at least 3 months after immunosuppressants.

• mitotane

  mitotane will decrease the level or effect of voclosporin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.

• nafcillin

  nafcillin will decrease the level or effect of voclosporin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.

• oxaliplatin

  oxaliplatin and voclosporin both increase QTc interval. Avoid or Use Alternate Drug.

• pentobarbital

  pentobarbital will decrease the level or effect of voclosporin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.

• pexidartinib

  pexidartinib will decrease the level or effect of voclosporin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.

• phenobarbital

  phenobarbital will decrease the level or effect of voclosporin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.

• phenytoin

  phenytoin will decrease the level or effect of voclosporin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.

• poliovirus vaccine live oral trivalent

  voclosporin decreases effects of poliovirus vaccine live oral trivalent by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Immunosuppressants also increase risk of infection with concomitant live vaccines. Avoid live vaccines for at least 3 months after immunosuppressants.

• primidone

  primidone will decrease the level or effect of voclosporin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.

• rifabutin

  rifabutin will decrease the level or effect of voclosporin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.

• rifapentine

  rifapentine will decrease the level or effect of voclosporin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.

• rotavirus oral vaccine, live

  voclosporin decreases effects of rotavirus oral vaccine, live by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Immunosuppressants also increase risk of infection with concomitant live vaccines. Avoid live vaccines for at least 3 months after immunosuppressants.

• rubella vaccine

  voclosporin decreases effects of rubella vaccine by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Immunosuppressants also increase risk of infection with concomitant live vaccines. Avoid live vaccines for at least 3 months after immunosuppressants.

• secobarbital

  secobarbital will decrease the level or effect of voclosporin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.

• sevoflurane

  sevoflurane and voclosporin both increase QTc interval. Avoid or Use Alternate Drug.

• siponimod

  siponimod and voclosporin both increase QTc interval. Avoid or Use Alternate Drug.

• smallpox (vaccinia) and monkeypox vaccine, live, nonreplicating

  voclosporin decreases effects of smallpox (vaccinia) vaccine, attenuated by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Immunosuppressants also increase risk of infection with concomitant live vaccines. Avoid live vaccines for at least 3 months after immunosuppressants.

• smallpox (vaccinia) vaccine, attenuated

  voclosporin decreases effects of smallpox (vaccinia) vaccine, attenuated by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Immunosuppressants also increase risk of infection with concomitant live vaccines. Avoid live vaccines for at least 3 months after immunosuppressants.

• smallpox (vaccinia) vaccine, live

  voclosporin decreases effects of smallpox (vaccinia) vaccine, live by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Immunosuppressants also increase risk of infection with concomitant live vaccines. Avoid live vaccines for at least 3 months after immunosuppressants.

• St John's Wort

  St John's Wort will decrease the level or effect of voclosporin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.

• telotristat ethyl

  telotristat ethyl will decrease the level or effect of voclosporin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.

• tisagenlecleucel

  voclosporin, tisagenlecleucel. Either increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug.

• typhoid polysaccharide vaccine

  voclosporin decreases effects of typhoid polysaccharide vaccine by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Immunosuppressants also increase risk of infection with concomitant live vaccines. Avoid live vaccines for at least 3 months after immunosuppressants.

• typhoid vaccine live

  voclosporin decreases effects of typhoid vaccine live by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Immunosuppressants also increase risk of infection with concomitant live vaccines. Avoid live vaccines for at least 3 months after immunosuppressants.

• upadacitinib

  voclosporin, upadacitinib. Either increases effects of the other by immunosuppressive effects; risk of infection. Contraindicated.

• varicella virus vaccine live

  voclosporin decreases effects of varicella virus vaccine live by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Immunosuppressants also increase risk of infection with concomitant live vaccines. Avoid live vaccines for at least 3 months after immunosuppressants.

• yellow fever vaccine

  voclosporin decreases effects of yellow fever vaccine by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Immunosuppressants also increase risk of infection with concomitant live vaccines. Avoid live vaccines for at least 3 months after immunosuppressants.

• zoster vaccine live

  voclosporin decreases effects of zoster vaccine live by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Immunosuppressants also increase risk of infection with concomitant live vaccines. Avoid live vaccines for at least 3 months after immunosuppressants.

Monitor Closely (355)

• adefovir

  voclosporin, adefovir. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• albuterol

  albuterol and voclosporin both increase QTc interval. Use Caution/Monitor.

• aldesleukin

  voclosporin, aldesleukin. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• alendronate

  voclosporin, alendronate. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• alfuzosin

  voclosporin, alfuzosin. Either increases effects of the other by QTc interval. Use Caution/Monitor.

• aliskiren

  voclosporin and aliskiren both increase serum potassium. Use Caution/Monitor.
  
  voclosporin, aliskiren. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• amikacin

  voclosporin, amikacin. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• amikacin liposome inhalation

  voclosporin, amikacin liposome inhalation. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• amiloride

  voclosporin and amiloride both increase serum potassium. Use Caution/Monitor.

• aminosalicylic acid

  voclosporin, aminosalicylic acid. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• amiodarone

  amiodarone will increase the level or effect of voclosporin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Reduce voclosporin daily dosage to 15.8 mg PO in AM and 7.9 mg PO in PM.
  
  voclosporin, amiodarone. Either increases effects of the other by QTc interval. Use Caution/Monitor.

• amitriptyline

  voclosporin, amitriptyline. Either increases effects of the other by QTc interval. Use Caution/Monitor.

• amoxapine

  voclosporin, amoxapine. Either increases effects of the other by QTc interval. Use Caution/Monitor.

• amphotericin B cholesteryl sulfate

  voclosporin, amphotericin B cholesteryl sulfate. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• amphotericin B deoxycholate

  voclosporin, amphotericin B deoxycholate. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• amphotericin B liposomal

  voclosporin, amphotericin B liposomal. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• amphotericin B phospholipid complex

  voclosporin, amphotericin B phospholipid complex. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• anidulafungin

  voclosporin, anidulafungin. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• anthrax vaccine adsorbed

  voclosporin decreases effects of anthrax vaccine adsorbed by immunosuppressive effects; risk of infection. Modify Therapy/Monitor Closely. Inactivated vaccines noted to be safe for administration may not be sufficiently immunogenic during treatment.

• apomorphine

  voclosporin, apomorphine. Either increases effects of the other by QTc interval. Use Caution/Monitor.

• aprepitant

  aprepitant will increase the level or effect of voclosporin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Reduce voclosporin daily dosage to 15.8 mg PO in AM and 7.9 mg PO in PM.

• arformoterol

  voclosporin, arformoterol. Either increases effects of the other by QTc interval. Use Caution/Monitor.

• aripiprazole

  aripiprazole and voclosporin both increase QTc interval. Use Caution/Monitor.

• arsenic trioxide

  voclosporin, arsenic trioxide. Either increases effects of the other by QTc interval. Use Caution/Monitor.

• artemether/lumefantrine

  voclosporin, artemether/lumefantrine. Either increases effects of the other by QTc interval. Use Caution/Monitor.

• asenapine

  voclosporin, asenapine. Either increases effects of the other by QTc interval. Use Caution/Monitor.

• asenapine transdermal

  voclosporin, asenapine transdermal. Either increases effects of the other by QTc interval. Use Caution/Monitor.

• aspirin

  voclosporin, aspirin. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• aspirin rectal

  voclosporin, aspirin rectal. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• atomoxetine

  atomoxetine and voclosporin both increase QTc interval. Use Caution/Monitor.

• azilsartan

  voclosporin and azilsartan both increase serum potassium. Use Caution/Monitor.
  
  voclosporin, azilsartan. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• azithromycin

  voclosporin, azithromycin. Either increases effects of the other by QTc interval. Use Caution/Monitor.

• balsalazide

  voclosporin, balsalazide. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• bedaquiline

  voclosporin, bedaquiline. Either increases effects of the other by QTc interval. Use Caution/Monitor.

• benazepril

  voclosporin and benazepril both increase serum potassium. Use Caution/Monitor.
  
  voclosporin, benazepril. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• berotralstat

  berotralstat will increase the level or effect of voclosporin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Reduce voclosporin daily dosage to 15.8 mg PO in AM and 7.9 mg PO in PM.

• bicalutamide

  bicalutamide will increase the level or effect of voclosporin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Reduce voclosporin daily dosage to 15.8 mg PO in AM and 7.9 mg PO in PM.

• bosutinib

  bosutinib and voclosporin both increase QTc interval. Use Caution/Monitor.

• canagliflozin

  voclosporin and canagliflozin both increase serum potassium. Use Caution/Monitor.

• candesartan

  voclosporin and candesartan both increase serum potassium. Use Caution/Monitor.
  
  voclosporin, candesartan. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• capecitabine

  capecitabine and voclosporin both increase QTc interval. Use Caution/Monitor.

• capreomycin

  voclosporin, capreomycin. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• captopril

  voclosporin and captopril both increase serum potassium. Use Caution/Monitor.
  
  voclosporin, captopril. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• carboplatin

  voclosporin, carboplatin. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• caspofungin

  voclosporin, caspofungin. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• cefaclor

  voclosporin, cefaclor. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• cefadroxil

  voclosporin, cefadroxil. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• cefazolin

  voclosporin, cefazolin. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• cefdinir

  voclosporin, cefdinir. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• cefditoren

  voclosporin, cefditoren. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• cefixime

  voclosporin, cefixime. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• cefotaxime

  voclosporin, cefotaxime. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• cefotetan

  voclosporin, cefotetan. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• cefoxitin

  voclosporin, cefoxitin. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• cefpodoxime

  voclosporin, cefpodoxime. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• cefprozil

  voclosporin, cefprozil. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• ceftazidime

  voclosporin, ceftazidime. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• ceftazidime/avibactam

  voclosporin, ceftazidime/avibactam. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• ceftibuten

  voclosporin, ceftibuten. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• ceftizoxime

  voclosporin, ceftizoxime. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• ceftriaxone

  voclosporin, ceftriaxone. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• cefuroxime

  voclosporin, cefuroxime. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• celecoxib

  voclosporin, celecoxib. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• cephalexin

  voclosporin, cephalexin. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• ceritinib

  ceritinib will increase the level or effect of voclosporin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Reduce voclosporin daily dosage to 15.8 mg PO in AM and 7.9 mg PO in PM.

• chlorpromazine

  voclosporin, chlorpromazine. Either increases effects of the other by QTc interval. Use Caution/Monitor.

• choline magnesium trisalicylate

  voclosporin, choline magnesium trisalicylate. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• cidofovir

  voclosporin, cidofovir. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• ciprofloxacin

  voclosporin, ciprofloxacin. Either increases effects of the other by QTc interval. Use Caution/Monitor.

• cisplatin

  voclosporin, cisplatin. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• citalopram

  voclosporin, citalopram. Either increases effects of the other by QTc interval. Use Caution/Monitor.

• clarithromycin

  voclosporin, clarithromycin. Either increases effects of the other by QTc interval. Use Caution/Monitor.

• clofazimine

  voclosporin, clofazimine. Either increases effects of the other by QTc interval. Use Caution/Monitor.

• clomipramine

  voclosporin, clomipramine. Either increases effects of the other by QTc interval. Use Caution/Monitor.

• clonidine

  voclosporin will increase the level or effect of clonidine by P-glycoprotein (MDR1) efflux transporter. Modify Therapy/Monitor Closely. Coadministration of voclosporin (a P-gp inhibitor) increases exposure and risk of adverse reactions of P-gp substrates. For certain P-gp substrates with a narrow therapeutic window, refer to prescribing information of these substrates for dosage modifications, if needed.

• clotrimazole

  clotrimazole will increase the level or effect of voclosporin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Reduce voclosporin daily dosage to 15.8 mg PO in AM and 7.9 mg PO in PM.

• clozapine

  voclosporin, clozapine. Either increases effects of the other by QTc interval. Use Caution/Monitor.

• colchicine

  voclosporin will increase the level or effect of colchicine by P-glycoprotein (MDR1) efflux transporter. Modify Therapy/Monitor Closely. Coadministration of voclosporin (a P-gp inhibitor) increases exposure and risk of adverse reactions of P-gp substrates. For certain P-gp substrates with a narrow therapeutic window, refer to prescribing information of these substrates for dosage modifications, if needed.

• colistin

  voclosporin, colistin. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• COVID-19 vaccine, adjuvanted-Novavax

  voclosporin decreases effects of COVID-19 vaccine, adjuvanted-Novavax by immunosuppressive effects; risk of infection. Modify Therapy/Monitor Closely. Inactivated vaccines noted to be safe for administration may not be sufficiently immunogenic during treatment.

• COVID-19 vaccine, mRNA-Pfizer

  voclosporin decreases effects of COVID-19 vaccine, mRNA-Pfizer by immunosuppressive effects; risk of infection. Modify Therapy/Monitor Closely. Inactivated vaccines noted to be safe for administration may not be sufficiently immunogenic during treatment.

• COVID-19 vaccine, viral vector-Janssen

  voclosporin decreases effects of COVID-19 vaccine, viral vector-Janssen by immunosuppressive effects; risk of infection. Modify Therapy/Monitor Closely. Inactivated vaccines noted to be safe for administration may not be sufficiently immunogenic during treatment.

• crizotinib

  crizotinib will increase the level or effect of voclosporin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Reduce voclosporin daily dosage to 15.8 mg PO in AM and 7.9 mg PO in PM.
  
  voclosporin, crizotinib. Either increases effects of the other by QTc interval. Use Caution/Monitor.

• cyclophosphamide

  voclosporin, cyclophosphamide. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• cyclosporine

  cyclosporine will increase the level or effect of voclosporin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Reduce voclosporin daily dosage to 15.8 mg PO in AM and 7.9 mg PO in PM.
  
  voclosporin and cyclosporine both increase serum potassium. Use Caution/Monitor.

• dasatinib

  voclosporin, dasatinib. Either increases effects of the other by QTc interval. Use Caution/Monitor.

• degarelix

  voclosporin, degarelix. Either increases effects of the other by QTc interval. Use Caution/Monitor.

• desipramine

  voclosporin, desipramine. Either increases effects of the other by QTc interval. Use Caution/Monitor.

• deutetrabenazine

  voclosporin, deutetrabenazine. Either increases effects of the other by QTc interval. Use Caution/Monitor. At the maximum recommended dose, deutetrabenazine does not prolong QT interval to a clinically relevant extent. Certain circumstances may increase risk of torsade de pointes and/or sudden death in association with drugs that prolong the QTc interval (eg, bradycardia, hypokalemia or hypomagnesemia, coadministration with other drugs that prolong QTc interval, presence of congenital QT prolongation).

• diatrizoate

  voclosporin, diatrizoate. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• diatrizoate meglumine/diatrizoate sodium

  voclosporin, diatrizoate meglumine/diatrizoate sodium. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• diclofenac

  voclosporin, diclofenac. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• diflunisal

  voclosporin, diflunisal. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• diltiazem

  diltiazem will increase the level or effect of voclosporin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Reduce voclosporin daily dosage to 15.8 mg PO in AM and 7.9 mg PO in PM.

• disopyramide

  voclosporin, disopyramide. Either increases effects of the other by QTc interval. Use Caution/Monitor.

• dofetilide

  voclosporin, dofetilide. Either increases effects of the other by QTc interval. Use Caution/Monitor.

• dolasetron

  voclosporin, dolasetron. Either increases effects of the other by QTc interval. Use Caution/Monitor.

• donepezil

  donepezil and voclosporin both increase QTc interval. Use Caution/Monitor.

• doxepin

  doxepin and voclosporin both increase QTc interval. Use Caution/Monitor.

• doxycycline

  doxycycline will increase the level or effect of voclosporin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Reduce voclosporin daily dosage to 15.8 mg PO in AM and 7.9 mg PO in PM.

• dronedarone

  dronedarone will increase the level or effect of voclosporin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Reduce voclosporin daily dosage to 15.8 mg PO in AM and 7.9 mg PO in PM.
  
  voclosporin, dronedarone. Either increases effects of the other by QTc interval. Use Caution/Monitor.

• droperidol

  voclosporin, droperidol. Either increases effects of the other by QTc interval. Use Caution/Monitor.

• drospirenone

  voclosporin and drospirenone both increase serum potassium. Use Caution/Monitor.

• eliglustat

  eliglustat and voclosporin both increase QTc interval. Use Caution/Monitor.

• elvitegravir

  voclosporin, elvitegravir. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• enalapril

  voclosporin and enalapril both increase serum potassium. Use Caution/Monitor.
  
  voclosporin, enalapril. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• encorafenib

  voclosporin, encorafenib. Either increases effects of the other by QTc interval. Use Caution/Monitor.

• entacapone

  entacapone will increase the level or effect of voclosporin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Reduce voclosporin daily dosage to 15.8 mg PO in AM and 7.9 mg PO in PM.

• entrectinib

  voclosporin, entrectinib. Either increases effects of the other by QTc interval. Use Caution/Monitor.

• eplerenone

  voclosporin and eplerenone both increase serum potassium. Use Caution/Monitor.

• eprosartan

  voclosporin and eprosartan both increase serum potassium. Use Caution/Monitor.
  
  voclosporin, eprosartan. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• eribulin

  voclosporin, eribulin. Either increases effects of the other by QTc interval. Use Caution/Monitor.

• erythromycin base

  erythromycin base will increase the level or effect of voclosporin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Reduce voclosporin daily dosage to 15.8 mg PO in AM and 7.9 mg PO in PM.
  
  voclosporin, erythromycin base. Either increases effects of the other by QTc interval. Use Caution/Monitor.

• erythromycin ethylsuccinate

  erythromycin ethylsuccinate will increase the level or effect of voclosporin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Reduce voclosporin daily dosage to 15.8 mg PO in AM and 7.9 mg PO in PM.
  
  voclosporin, erythromycin ethylsuccinate. Either increases effects of the other by QTc interval. Use Caution/Monitor.

• erythromycin lactobionate

  erythromycin lactobionate will increase the level or effect of voclosporin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Reduce voclosporin daily dosage to 15.8 mg PO in AM and 7.9 mg PO in PM.
  
  voclosporin, erythromycin lactobionate. Either increases effects of the other by QTc interval. Use Caution/Monitor.

• erythromycin stearate

  erythromycin stearate will increase the level or effect of voclosporin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Reduce voclosporin daily dosage to 15.8 mg PO in AM and 7.9 mg PO in PM.
  
  voclosporin, erythromycin stearate. Either increases effects of the other by QTc interval. Use Caution/Monitor.

• escitalopram

  voclosporin, escitalopram. Either increases effects of the other by QTc interval. Use Caution/Monitor.

• ethiodized oil

  voclosporin, ethiodized oil. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• etidronate

  voclosporin, etidronate. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• etodolac

  voclosporin, etodolac. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• everolimus

  voclosporin, everolimus. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• ezogabine

  voclosporin, ezogabine. Either increases effects of the other by QTc interval. Use Caution/Monitor.

• fedratinib

  fedratinib will increase the level or effect of voclosporin by affecting hepatic enzyme CYP2E1 metabolism. Modify Therapy/Monitor Closely. Reduce voclosporin daily dosage to 15.8 mg PO in AM and 7.9 mg PO in PM.

• fenoprofen

  voclosporin, fenoprofen. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• finerenone

  voclosporin and finerenone both increase serum potassium. Use Caution/Monitor.

• fingolimod

  fingolimod and voclosporin both increase QTc interval. Use Caution/Monitor.

• flecainide

  voclosporin, flecainide. Either increases effects of the other by QTc interval. Use Caution/Monitor.

• fluconazole

  fluconazole will increase the level or effect of voclosporin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Reduce voclosporin daily dosage to 15.8 mg PO in AM and 7.9 mg PO in PM.
  
  voclosporin, fluconazole. Either increases effects of the other by QTc interval. Use Caution/Monitor.
  
  voclosporin, fluconazole. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• flucytosine

  voclosporin, flucytosine. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• fluoxetine

  voclosporin, fluoxetine. Either increases effects of the other by QTc interval. Use Caution/Monitor.

• flurbiprofen

  voclosporin, flurbiprofen. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• fluvoxamine

  fluvoxamine will increase the level or effect of voclosporin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Reduce voclosporin daily dosage to 15.8 mg PO in AM and 7.9 mg PO in PM.

• fosamprenavir

  fosamprenavir will increase the level or effect of voclosporin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Reduce voclosporin daily dosage to 15.8 mg PO in AM and 7.9 mg PO in PM.

• fosaprepitant

  fosaprepitant will increase the level or effect of voclosporin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Reduce voclosporin daily dosage to 15.8 mg PO in AM and 7.9 mg PO in PM.

• foscarnet

  voclosporin, foscarnet. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• fosinopril

  voclosporin and fosinopril both increase serum potassium. Use Caution/Monitor.
  
  voclosporin, fosinopril. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• gadobenate

  voclosporin, gadobenate. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• gadobutrol

  voclosporin, gadobutrol. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• gadodiamide

  voclosporin, gadodiamide. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• gadofosveset

  voclosporin, gadofosveset. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• gadopentetate

  voclosporin, gadopentetate. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• gadoterate meglumine

  voclosporin, gadoterate meglumine. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• gadoteridol

  voclosporin, gadoteridol. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• gadoversetamide

  voclosporin, gadoversetamide. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• gadoxetate

  voclosporin, gadoxetate. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• ganciclovir

  voclosporin, ganciclovir. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• gemifloxacin

  gemifloxacin and voclosporin both increase QTc interval. Use Caution/Monitor.

• gemtuzumab

  voclosporin, gemtuzumab. Either increases effects of the other by QTc interval. Use Caution/Monitor.

• gentamicin

  voclosporin, gentamicin. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• gilteritinib

  gilteritinib and voclosporin both increase QTc interval. Use Caution/Monitor.

• glasdegib

  voclosporin, glasdegib. Either increases effects of the other by QTc interval. Use Caution/Monitor.

• granisetron

  granisetron and voclosporin both increase QTc interval. Use Caution/Monitor.

• griseofulvin

  voclosporin, griseofulvin. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• haemophilus influenzae type b vaccine

  voclosporin decreases effects of haemophilus influenzae type b vaccine by immunosuppressive effects; risk of infection. Modify Therapy/Monitor Closely. Inactivated vaccines noted to be safe for administration may not be sufficiently immunogenic during treatment.

• haloperidol

  haloperidol will increase the level or effect of voclosporin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Reduce voclosporin daily dosage to 15.8 mg PO in AM and 7.9 mg PO in PM.
  
  voclosporin, haloperidol. Either increases effects of the other by QTc interval. Use Caution/Monitor.

• heparin

  voclosporin and heparin both increase serum potassium. Use Caution/Monitor.

• hepatitis A vaccine inactivated

  voclosporin decreases effects of hepatitis A vaccine inactivated by immunosuppressive effects; risk of infection. Modify Therapy/Monitor Closely. Inactivated vaccines noted to be safe for administration may not be sufficiently immunogenic during treatment.

• hepatitis a/b vaccine

  voclosporin decreases effects of hepatitis a/b vaccine by immunosuppressive effects; risk of infection. Modify Therapy/Monitor Closely. Inactivated vaccines noted to be safe for administration may not be sufficiently immunogenic during treatment.

• hepatitis b vaccine

  voclosporin decreases effects of hepatitis b vaccine by immunosuppressive effects; risk of infection. Modify Therapy/Monitor Closely. Inactivated vaccines noted to be safe for administration may not be sufficiently immunogenic during treatment.

• HIV vaccine

  voclosporin decreases effects of HIV vaccine by immunosuppressive effects; risk of infection. Modify Therapy/Monitor Closely. Inactivated vaccines noted to be safe for administration may not be sufficiently immunogenic during treatment.

• human papillomavirus vaccine, bivalent

  voclosporin decreases effects of human papillomavirus vaccine, bivalent by immunosuppressive effects; risk of infection. Modify Therapy/Monitor Closely. Inactivated vaccines noted to be safe for administration may not be sufficiently immunogenic during treatment.

• human papillomavirus vaccine, nonavalent

  voclosporin decreases effects of human papillomavirus vaccine, nonavalent by immunosuppressive effects; risk of infection. Modify Therapy/Monitor Closely. Inactivated vaccines noted to be safe for administration may not be sufficiently immunogenic during treatment.

• human papillomavirus vaccine, quadrivalent

  voclosporin decreases effects of human papillomavirus vaccine, quadrivalent by immunosuppressive effects; risk of infection. Modify Therapy/Monitor Closely. Inactivated vaccines noted to be safe for administration may not be sufficiently immunogenic during treatment.

• hydroxychloroquine sulfate

  voclosporin, hydroxychloroquine sulfate. Either increases effects of the other by QTc interval. Use Caution/Monitor.

• hydroxyzine

  hydroxyzine and voclosporin both increase QTc interval. Use Caution/Monitor.

• ibandronate

  voclosporin, ibandronate. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• ibrexafungerp

  voclosporin, ibrexafungerp. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• ibuprofen

  voclosporin, ibuprofen. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• ibuprofen IV

  voclosporin, ibuprofen IV. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• ibuprofen/famotidine

  voclosporin, ibuprofen/famotidine. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• ibutilide

  voclosporin, ibutilide. Either increases effects of the other by QTc interval. Use Caution/Monitor.

• ifosfamide

  voclosporin, ifosfamide. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• iloperidone

  iloperidone will increase the level or effect of voclosporin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Reduce voclosporin daily dosage to 15.8 mg PO in AM and 7.9 mg PO in PM.
  
  voclosporin, iloperidone. Either increases effects of the other by QTc interval. Use Caution/Monitor.

• imatinib

  imatinib will increase the level or effect of voclosporin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Reduce voclosporin daily dosage to 15.8 mg PO in AM and 7.9 mg PO in PM.

• indacaterol, inhaled

  voclosporin, indacaterol, inhaled. Either increases effects of the other by QTc interval. Use Caution/Monitor.

• indapamide

  voclosporin, indapamide. Either increases effects of the other by QTc interval. Use Caution/Monitor.

• indomethacin

  voclosporin, indomethacin. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• influenza A (H5N1) vaccine

  voclosporin decreases effects of influenza A (H5N1) vaccine by immunosuppressive effects; risk of infection. Modify Therapy/Monitor Closely. Inactivated vaccines noted to be safe for administration may not be sufficiently immunogenic during treatment.

• influenza virus vaccine (H5N1), adjuvanted

  voclosporin decreases effects of influenza virus vaccine (H5N1), adjuvanted by immunosuppressive effects; risk of infection. Modify Therapy/Monitor Closely. Inactivated vaccines noted to be safe for administration may not be sufficiently immunogenic during treatment.

• influenza virus vaccine quadrivalent

  voclosporin decreases effects of influenza virus vaccine quadrivalent by immunosuppressive effects; risk of infection. Modify Therapy/Monitor Closely. Inactivated vaccines noted to be safe for administration may not be sufficiently immunogenic during treatment.

• influenza virus vaccine quadrivalent, adjuvanted

  voclosporin decreases effects of influenza virus vaccine quadrivalent, adjuvanted by immunosuppressive effects; risk of infection. Modify Therapy/Monitor Closely. Inactivated vaccines noted to be safe for administration may not be sufficiently immunogenic during treatment.

• influenza virus vaccine quadrivalent, cell-cultured

  voclosporin decreases effects of influenza virus vaccine quadrivalent, cell-cultured by immunosuppressive effects; risk of infection. Modify Therapy/Monitor Closely. Inactivated vaccines noted to be safe for administration may not be sufficiently immunogenic during treatment.

• influenza virus vaccine quadrivalent, recombinant

  voclosporin decreases effects of influenza virus vaccine quadrivalent, recombinant by immunosuppressive effects; risk of infection. Modify Therapy/Monitor Closely. Inactivated vaccines noted to be safe for administration may not be sufficiently immunogenic during treatment.

• influenza virus vaccine trivalent

  voclosporin decreases effects of influenza virus vaccine trivalent by immunosuppressive effects; risk of infection. Modify Therapy/Monitor Closely. Inactivated vaccines noted to be safe for administration may not be sufficiently immunogenic during treatment.

• influenza virus vaccine trivalent, adjuvanted

  voclosporin decreases effects of influenza virus vaccine trivalent, adjuvanted by immunosuppressive effects; risk of infection. Modify Therapy/Monitor Closely. Inactivated vaccines noted to be safe for administration may not be sufficiently immunogenic during treatment.

• influenza virus vaccine trivalent, recombinant

  voclosporin decreases effects of influenza virus vaccine trivalent, recombinant by immunosuppressive effects; risk of infection. Modify Therapy/Monitor Closely. Inactivated vaccines noted to be safe for administration may not be sufficiently immunogenic during treatment.

• inotersen

  voclosporin, inotersen. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• inotuzumab

  voclosporin, inotuzumab. Either increases effects of the other by QTc interval. Use Caution/Monitor.

• iodixanol

  voclosporin, iodixanol. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• ioflupane I 123

  voclosporin, ioflupane I 123. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• iohexol

  voclosporin, iohexol. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• iopamidol

  voclosporin, iopamidol. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• iopromide

  voclosporin, iopromide. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• ioversol

  voclosporin, ioversol. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• ioxilan

  voclosporin, ioxilan. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• irbesartan

  voclosporin and irbesartan both increase serum potassium. Use Caution/Monitor.
  
  voclosporin, irbesartan. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• isradipine

  voclosporin, isradipine. Either increases effects of the other by QTc interval. Use Caution/Monitor.

• itraconazole

  voclosporin, itraconazole. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• ivacaftor

  ivacaftor will increase the level or effect of voclosporin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Reduce voclosporin daily dosage to 15.8 mg PO in AM and 7.9 mg PO in PM.

• Japanese encephalitis virus vaccine

  voclosporin decreases effects of Japanese encephalitis virus vaccine by immunosuppressive effects; risk of infection. Modify Therapy/Monitor Closely. Inactivated vaccines noted to be safe for administration may not be sufficiently immunogenic during treatment.

• kanamycin

  voclosporin, kanamycin. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• ketoconazole

  voclosporin, ketoconazole. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• ketoprofen

  voclosporin, ketoprofen. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• ketorolac

  voclosporin, ketorolac. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• ketorolac intranasal

  voclosporin, ketorolac intranasal. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• lapatinib

  lapatinib will increase the level or effect of voclosporin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Reduce voclosporin daily dosage to 15.8 mg PO in AM and 7.9 mg PO in PM.
  
  voclosporin, lapatinib. Either increases effects of the other by QTc interval. Use Caution/Monitor.

• larotrectinib

  larotrectinib will increase the level or effect of voclosporin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Reduce voclosporin daily dosage to 15.8 mg PO in AM and 7.9 mg PO in PM.

• lefamulin

  lefamulin will increase the level or effect of voclosporin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Reduce voclosporin daily dosage to 15.8 mg PO in AM and 7.9 mg PO in PM.
  
  voclosporin, lefamulin. Either increases effects of the other by QTc interval. Use Caution/Monitor.

• letermovir

  letermovir will increase the level or effect of voclosporin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Reduce voclosporin daily dosage to 15.8 mg PO in AM and 7.9 mg PO in PM.
  
  voclosporin, letermovir. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• levofloxacin

  voclosporin, levofloxacin. Either increases effects of the other by QTc interval. Use Caution/Monitor.

• levoketoconazole

  voclosporin, levoketoconazole. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• lisinopril

  voclosporin and lisinopril both increase serum potassium. Use Caution/Monitor.
  
  voclosporin, lisinopril. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• lithium

  lithium and voclosporin both increase QTc interval. Use Caution/Monitor.

• lofexidine

  voclosporin, lofexidine. Either increases effects of the other by QTc interval. Use Caution/Monitor.

• lopinavir

  voclosporin, lopinavir. Either increases effects of the other by QTc interval. Use Caution/Monitor.

• losartan

  voclosporin and losartan both increase serum potassium. Use Caution/Monitor.
  
  voclosporin, losartan. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• mannitol

  voclosporin, mannitol. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• maprotiline

  voclosporin, maprotiline. Either increases effects of the other by QTc interval. Use Caution/Monitor.

• maribavir

  voclosporin, maribavir. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• meclofenamate

  voclosporin, meclofenamate. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• mefenamic acid

  voclosporin, mefenamic acid. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• mefloquine

  voclosporin, mefloquine. Either increases effects of the other by QTc interval. Use Caution/Monitor.

• meloxicam

  voclosporin, meloxicam. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• melphalan

  voclosporin, melphalan. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• meningococcal A C Y and W polysaccharide tetanus toxoid conjugate vaccine

  voclosporin decreases effects of meningococcal A C Y and W polysaccharide tetanus toxoid conjugate vaccine by immunosuppressive effects; risk of infection. Modify Therapy/Monitor Closely. Inactivated vaccines noted to be safe for administration may not be sufficiently immunogenic during treatment.

• meningococcal A C Y and W-135 diphtheria conjugate vaccine

  voclosporin decreases effects of meningococcal A C Y and W-135 diphtheria conjugate vaccine by immunosuppressive effects; risk of infection. Modify Therapy/Monitor Closely. Inactivated vaccines noted to be safe for administration may not be sufficiently immunogenic during treatment.

• meningococcal A C Y and W-135 polysaccharide vaccine combined

  voclosporin decreases effects of meningococcal A C Y and W-135 polysaccharide vaccine combined by immunosuppressive effects; risk of infection. Modify Therapy/Monitor Closely. Inactivated vaccines noted to be safe for administration may not be sufficiently immunogenic during treatment.

• meningococcal C and Y/haemophilus influenza type B vaccine

  voclosporin decreases effects of meningococcal C and Y/haemophilus influenza type B vaccine by immunosuppressive effects; risk of infection. Modify Therapy/Monitor Closely. Inactivated vaccines noted to be safe for administration may not be sufficiently immunogenic during treatment.

• meningococcal group B vaccine

  voclosporin decreases effects of meningococcal group B vaccine by immunosuppressive effects; risk of infection. Modify Therapy/Monitor Closely. Inactivated vaccines noted to be safe for administration may not be sufficiently immunogenic during treatment.

• mesalamine

  voclosporin, mesalamine. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• mesalamine rectal

  voclosporin, mesalamine rectal. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• methadone

  voclosporin, methadone. Either increases effects of the other by QTc interval. Use Caution/Monitor.

• methotrexate

  voclosporin, methotrexate. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• metronidazole

  metronidazole will increase the level or effect of voclosporin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Reduce voclosporin daily dosage to 15.8 mg PO in AM and 7.9 mg PO in PM.

• micafungin

  voclosporin, micafungin. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• mifepristone

  voclosporin, mifepristone. Either increases effects of the other by QTc interval. Use Caution/Monitor.

• mirtazapine

  mirtazapine and voclosporin both increase QTc interval. Use Caution/Monitor.

• moexipril

  voclosporin and moexipril both increase serum potassium. Use Caution/Monitor.
  
  voclosporin, moexipril. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• moxifloxacin

  voclosporin, moxifloxacin. Either increases effects of the other by QTc interval. Use Caution/Monitor.

• nabumetone

  voclosporin, nabumetone. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• naproxen

  voclosporin, naproxen. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• neomycin PO

  voclosporin, neomycin PO. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• netupitant/palonosetron

  netupitant/palonosetron will increase the level or effect of voclosporin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Reduce voclosporin daily dosage to 15.8 mg PO in AM and 7.9 mg PO in PM.

• nilotinib

  voclosporin, nilotinib. Either increases effects of the other by QTc interval. Use Caution/Monitor.

• nortriptyline

  voclosporin, nortriptyline. Either increases effects of the other by QTc interval. Use Caution/Monitor.

• nystatin

  voclosporin, nystatin. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• octreotide

  voclosporin, octreotide. Either increases effects of the other by QTc interval. Use Caution/Monitor.

• ofloxacin

  voclosporin, ofloxacin. Either increases effects of the other by QTc interval. Use Caution/Monitor.

• olanzapine

  voclosporin, olanzapine. Either increases effects of the other by QTc interval. Use Caution/Monitor.

• olmesartan

  voclosporin and olmesartan both increase serum potassium. Use Caution/Monitor.
  
  voclosporin, olmesartan. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• olsalazine

  voclosporin, olsalazine. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• ondansetron

  voclosporin, ondansetron. Either increases effects of the other by QTc interval. Use Caution/Monitor.

• osilodrostat

  voclosporin, osilodrostat. Either increases effects of the other by QTc interval. Use Caution/Monitor.

• osimertinib

  voclosporin, osimertinib. Either increases effects of the other by QTc interval. Use Caution/Monitor.

• oteseconazole

  voclosporin, oteseconazole. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• oxaprozin

  voclosporin, oxaprozin. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• ozanimod

  voclosporin, ozanimod. Either increases effects of the other by QTc interval. Use Caution/Monitor.

• paliperidone

  voclosporin, paliperidone. Either increases effects of the other by QTc interval. Use Caution/Monitor.

• panobinostat

  voclosporin, panobinostat. Either increases effects of the other by QTc interval. Use Caution/Monitor.

• pasireotide

  voclosporin, pasireotide. Either increases effects of the other by QTc interval. Use Caution/Monitor.

• pazopanib

  voclosporin, pazopanib. Either increases effects of the other by QTc interval. Use Caution/Monitor.

• pentamidine

  voclosporin and pentamidine both increase serum potassium. Use Caution/Monitor.
  
  voclosporin, pentamidine. Either increases effects of the other by QTc interval. Use Caution/Monitor.
  
  voclosporin, pentamidine. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• perindopril

  voclosporin and perindopril both increase serum potassium. Use Caution/Monitor.
  
  voclosporin, perindopril. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• pimavanserin

  voclosporin, pimavanserin. Either increases effects of the other by QTc interval. Use Caution/Monitor.

• pimozide

  voclosporin, pimozide. Either increases effects of the other by QTc interval. Use Caution/Monitor.

• piroxicam

  voclosporin, piroxicam. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• pitolisant

  voclosporin, pitolisant. Either increases effects of the other by QTc interval. Use Caution/Monitor.

• plazomicin

  voclosporin, plazomicin. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• pneumococcal vaccine 13-valent

  voclosporin decreases effects of pneumococcal vaccine 13-valent by immunosuppressive effects; risk of infection. Modify Therapy/Monitor Closely. Inactivated vaccines noted to be safe for administration may not be sufficiently immunogenic during treatment.

• pneumococcal vaccine 15-valent

  voclosporin decreases effects of pneumococcal vaccine 15-valent by immunosuppressive effects; risk of infection. Modify Therapy/Monitor Closely. Inactivated vaccines noted to be safe for administration may not be sufficiently immunogenic during treatment.

• pneumococcal vaccine 20-valent

  voclosporin decreases effects of pneumococcal vaccine 20-valent by immunosuppressive effects; risk of infection. Modify Therapy/Monitor Closely. Inactivated vaccines noted to be safe for administration may not be sufficiently immunogenic during treatment.

• pneumococcal vaccine heptavalent

  voclosporin decreases effects of pneumococcal vaccine heptavalent by immunosuppressive effects; risk of infection. Modify Therapy/Monitor Closely. Inactivated vaccines noted to be safe for administration may not be sufficiently immunogenic during treatment.

• pneumococcal vaccine polyvalent

  voclosporin decreases effects of pneumococcal vaccine polyvalent by immunosuppressive effects; risk of infection. Modify Therapy/Monitor Closely. Inactivated vaccines noted to be safe for administration may not be sufficiently immunogenic during treatment.

• poliovirus vaccine inactivated

  voclosporin decreases effects of poliovirus vaccine inactivated by immunosuppressive effects; risk of infection. Modify Therapy/Monitor Closely. Inactivated vaccines noted to be safe for administration may not be sufficiently immunogenic during treatment.

• polymyxin B

  voclosporin, polymyxin B. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• posaconazole

  voclosporin, posaconazole. Either increases effects of the other by QTc interval. Use Caution/Monitor.
  
  voclosporin, posaconazole. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• potassium acid phosphate

  voclosporin and potassium acid phosphate both increase serum potassium. Use Caution/Monitor.

• potassium chloride

  voclosporin and potassium chloride both increase serum potassium. Use Caution/Monitor.

• potassium citrate

  voclosporin and potassium citrate both increase serum potassium. Use Caution/Monitor.

• potassium citrate/citric acid

  voclosporin and potassium citrate/citric acid both increase serum potassium. Use Caution/Monitor.

• potassium phosphates, IV

  voclosporin and potassium phosphates, IV both increase serum potassium. Use Caution/Monitor.

• primaquine

  primaquine and voclosporin both increase QTc interval. Use Caution/Monitor.

• procainamide

  voclosporin, procainamide. Either increases effects of the other by QTc interval. Use Caution/Monitor.

• protriptyline

  voclosporin, protriptyline. Either increases effects of the other by QTc interval. Use Caution/Monitor.

• quetiapine

  voclosporin, quetiapine. Either increases effects of the other by QTc interval. Use Caution/Monitor.

• quinapril

  voclosporin and quinapril both increase serum potassium. Use Caution/Monitor.
  
  voclosporin, quinapril. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• quinidine

  voclosporin, quinidine. Either increases effects of the other by QTc interval. Use Caution/Monitor.

• quinine

  voclosporin, quinine. Either increases effects of the other by QTc interval. Use Caution/Monitor.

• rabies vaccine

  voclosporin decreases effects of rabies vaccine by immunosuppressive effects; risk of infection. Modify Therapy/Monitor Closely. Inactivated vaccines noted to be safe for administration may not be sufficiently immunogenic during treatment.

• rabies vaccine chick embryo cell derived

  voclosporin decreases effects of rabies vaccine chick embryo cell derived by immunosuppressive effects; risk of infection. Modify Therapy/Monitor Closely. Inactivated vaccines noted to be safe for administration may not be sufficiently immunogenic during treatment.

• ramipril

  voclosporin and ramipril both increase serum potassium. Use Caution/Monitor.
  
  voclosporin, ramipril. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• ranolazine

  voclosporin, ranolazine. Either increases effects of the other by QTc interval. Use Caution/Monitor.

• ribociclib

  ribociclib will increase the level or effect of voclosporin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Reduce voclosporin daily dosage to 15.8 mg PO in AM and 7.9 mg PO in PM.
  
  voclosporin, ribociclib. Either increases effects of the other by QTc interval. Use Caution/Monitor.

• rilpivirine

  voclosporin, rilpivirine. Either increases effects of the other by QTc interval. Use Caution/Monitor.

• risedronate

  voclosporin, risedronate. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• risperidone

  voclosporin, risperidone. Either increases effects of the other by QTc interval. Use Caution/Monitor.

• ritonavir

  voclosporin, ritonavir. Either increases effects of the other by QTc interval. Use Caution/Monitor.

• romidepsin

  voclosporin, romidepsin. Either increases effects of the other by QTc interval. Use Caution/Monitor.

• sacubitril/valsartan

  voclosporin and sacubitril/valsartan both increase serum potassium. Use Caution/Monitor.
  
  voclosporin, sacubitril/valsartan. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• salsalate

  voclosporin, salsalate. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• saquinavir

  voclosporin, saquinavir. Either increases effects of the other by QTc interval. Use Caution/Monitor.

• SARS-CoV-2 vaccine, inactivated

  voclosporin decreases effects of SARS-CoV-2 vaccine, inactivated by immunosuppressive effects; risk of infection. Modify Therapy/Monitor Closely. Inactivated vaccines noted to be safe for administration may not be sufficiently immunogenic during treatment.

• schisandra

  schisandra will increase the level or effect of voclosporin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Reduce voclosporin daily dosage to 15.8 mg PO in AM and 7.9 mg PO in PM.

• selpercatinib

  voclosporin, selpercatinib. Either increases effects of the other by QTc interval. Use Caution/Monitor.

• sertraline

  sertraline will increase the level or effect of voclosporin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Reduce voclosporin daily dosage to 15.8 mg PO in AM and 7.9 mg PO in PM.
  
  voclosporin, sertraline. Either increases effects of the other by QTc interval. Use Caution/Monitor.

• sirolimus

  voclosporin will increase the level or effect of sirolimus by P-glycoprotein (MDR1) efflux transporter. Modify Therapy/Monitor Closely. Coadministration of voclosporin (a P-gp inhibitor) increases exposure and risk of adverse reactions of P-gp substrates. For certain P-gp substrates with a narrow therapeutic window, refer to prescribing information of these substrates for dosage modifications, if needed.

• sodium phosphates, IV

  voclosporin, sodium phosphates, IV. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• solifenacin

  voclosporin, solifenacin. Either increases effects of the other by QTc interval. Use Caution/Monitor.

• sorafenib

  voclosporin, sorafenib. Either increases effects of the other by QTc interval. Use Caution/Monitor.

• sotalol

  voclosporin, sotalol. Either increases effects of the other by QTc interval. Use Caution/Monitor.

• spironolactone

  voclosporin and spironolactone both increase serum potassium. Use Caution/Monitor.

• streptomycin

  voclosporin, streptomycin. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• streptozocin

  voclosporin, streptozocin. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• succinylcholine

  voclosporin and succinylcholine both increase serum potassium. Use Caution/Monitor.

• sulfadiazine

  voclosporin, sulfadiazine. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• sulfasalazine

  voclosporin, sulfasalazine. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• sulfisoxazole

  voclosporin, sulfisoxazole. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• sulindac

  voclosporin, sulindac. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• sunitinib

  voclosporin, sunitinib. Either increases effects of the other by QTc interval. Use Caution/Monitor.

• tacrolimus

  voclosporin and tacrolimus both increase serum potassium. Use Caution/Monitor.
  
  voclosporin, tacrolimus. Either increases effects of the other by QTc interval. Use Caution/Monitor.

• telavancin

  voclosporin, telavancin. Either increases effects of the other by QTc interval. Use Caution/Monitor.

• telmisartan

  voclosporin and telmisartan both increase serum potassium. Use Caution/Monitor.
  
  voclosporin, telmisartan. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• temsirolimus

  voclosporin will increase the level or effect of temsirolimus by P-glycoprotein (MDR1) efflux transporter. Modify Therapy/Monitor Closely. Coadministration of voclosporin (a P-gp inhibitor) increases exposure and risk of adverse reactions of P-gp substrates. For certain P-gp substrates with a narrow therapeutic window, refer to prescribing information of these substrates for dosage modifications, if needed.

• tenofovir AF

  voclosporin, tenofovir AF. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• tenofovir DF

  voclosporin, tenofovir DF. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• terbinafine

  voclosporin, terbinafine. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• tetanus toxoid adsorbed or fluid

  voclosporin decreases effects of tetanus toxoid adsorbed or fluid by immunosuppressive effects; risk of infection. Modify Therapy/Monitor Closely. Inactivated vaccines noted to be safe for administration may not be sufficiently immunogenic during treatment.

• tetrabenazine

  voclosporin, tetrabenazine. Either increases effects of the other by QTc interval. Use Caution/Monitor.

• tetracycline

  tetracycline will increase the level or effect of voclosporin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Reduce voclosporin daily dosage to 15.8 mg PO in AM and 7.9 mg PO in PM.

• thioridazine

  voclosporin, thioridazine. Either increases effects of the other by QTc interval. Use Caution/Monitor.

• thiothixene

  voclosporin, thiothixene. Either increases effects of the other by QTc interval. Use Caution/Monitor.

• tick-borne encephalitis vaccine

  voclosporin decreases effects of tick-borne encephalitis vaccine by immunosuppressive effects; risk of infection. Modify Therapy/Monitor Closely. Inactivated vaccines noted to be safe for administration may not be sufficiently immunogenic during treatment.

• tiludronate

  voclosporin, tiludronate. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• tobramycin

  voclosporin, tobramycin. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• tobramycin inhaled

  voclosporin, tobramycin inhaled. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• tolmetin

  voclosporin, tolmetin. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• trandolapril

  voclosporin and trandolapril both increase serum potassium. Use Caution/Monitor.
  
  voclosporin, trandolapril. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• triamterene

  voclosporin and triamterene both increase serum potassium. Use Caution/Monitor.

• trimethoprim

  voclosporin and trimethoprim both decrease serum potassium. Use Caution/Monitor.

• trimipramine

  voclosporin, trimipramine. Either increases effects of the other by QTc interval. Use Caution/Monitor.

• ublituximab

  ublituximab and voclosporin both increase immunosuppressive effects; risk of infection. Modify Therapy/Monitor Closely. Owing to potential additive immunosuppressive effects, consider duration of effect and mechanism of action of these therapies if coadministered

• umeclidinium bromide/vilanterol inhaled

  voclosporin, umeclidinium bromide/vilanterol inhaled. Either increases effects of the other by QTc interval. Use Caution/Monitor.

• valganciclovir

  voclosporin, valganciclovir. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• valsartan

  voclosporin and valsartan both increase serum potassium. Use Caution/Monitor.
  
  voclosporin, valsartan. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• vancomycin

  voclosporin, vancomycin. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• vandetanib

  voclosporin, vandetanib. Either increases effects of the other by QTc interval. Use Caution/Monitor.

• vardenafil

  voclosporin, vardenafil. Either increases effects of the other by QTc interval. Use Caution/Monitor.

• vemurafenib

  voclosporin, vemurafenib. Either increases effects of the other by QTc interval. Use Caution/Monitor.

• verapamil

  verapamil will increase the level or effect of voclosporin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Reduce voclosporin daily dosage to 15.8 mg PO in AM and 7.9 mg PO in PM.

• voriconazole

  voclosporin, voriconazole. Either increases effects of the other by QTc interval. Use Caution/Monitor.
  
  voclosporin, voriconazole. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• vorinostat

  voclosporin, vorinostat. Either increases effects of the other by QTc interval. Use Caution/Monitor.

• voxelotor

  voxelotor will increase the level or effect of voclosporin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Reduce voclosporin daily dosage to 15.8 mg PO in AM and 7.9 mg PO in PM.

• ziprasidone

  voclosporin, ziprasidone. Either increases effects of the other by QTc interval. Use Caution/Monitor.

• zoledronic acid

  voclosporin, zoledronic acid. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• zoster vaccine recombinant

  voclosporin decreases effects of zoster vaccine recombinant by immunosuppressive effects; risk of infection. Modify Therapy/Monitor Closely. Inactivated vaccines noted to be safe for administration may not be sufficiently immunogenic during treatment.

Minor (30)

• ambrisentan

  voclosporin will increase the level or effect of ambrisentan by Other (see comment). Minor/Significance Unknown. Information suggests voclosporin (an OATP1B1 inhibitor) may increase in the concentration of OATP1B1 substrates is possible. Monitor for adverse reactions of OATP1B1 substrates when coadministered with voclosporin.

• atorvastatin

  voclosporin will increase the level or effect of atorvastatin by Other (see comment). Minor/Significance Unknown. Information suggests voclosporin (an OATP1B1 inhibitor) may increase in the concentration of OATP1B1 substrates is possible. Monitor for adverse reactions of OATP1B1 substrates when coadministered with voclosporin.

• bosentan

  voclosporin will increase the level or effect of bosentan by Other (see comment). Minor/Significance Unknown. Information suggests voclosporin (an OATP1B1 inhibitor) may increase in the concentration of OATP1B1 substrates is possible. Monitor for adverse reactions of OATP1B1 substrates when coadministered with voclosporin.

• caspofungin

  voclosporin will increase the level or effect of caspofungin by Other (see comment). Minor/Significance Unknown. Information suggests voclosporin (an OATP1B1 inhibitor) may increase in the concentration of OATP1B1 substrates is possible. Monitor for adverse reactions of OATP1B1 substrates when coadministered with voclosporin.

• elagolix

  voclosporin will increase the level or effect of elagolix by Other (see comment). Minor/Significance Unknown. Information suggests voclosporin (an OATP1B1 inhibitor) may increase in the concentration of OATP1B1 substrates is possible. Monitor for adverse reactions of OATP1B1 substrates when coadministered with voclosporin.

• elbasvir/grazoprevir

  voclosporin will increase the level or effect of elbasvir/grazoprevir by Other (see comment). Minor/Significance Unknown. Information suggests voclosporin (an OATP1B1 inhibitor) may increase in the concentration of OATP1B1 substrates is possible. Monitor for adverse reactions of OATP1B1 substrates when coadministered with voclosporin.

• eluxadoline

  voclosporin will increase the level or effect of eluxadoline by Other (see comment). Minor/Significance Unknown. Information suggests voclosporin (an OATP1B1 inhibitor) may increase in the concentration of OATP1B1 substrates is possible. Monitor for adverse reactions of OATP1B1 substrates when coadministered with voclosporin.

• enalapril

  voclosporin will increase the level or effect of enalapril by Other (see comment). Minor/Significance Unknown. Information suggests voclosporin (an OATP1B1 inhibitor) may increase in the concentration of OATP1B1 substrates is possible. Monitor for adverse reactions of OATP1B1 substrates when coadministered with voclosporin.

• ezetimibe

  voclosporin will increase the level or effect of ezetimibe by Other (see comment). Minor/Significance Unknown. Information suggests voclosporin (an OATP1B1 inhibitor) may increase in the concentration of OATP1B1 substrates is possible. Monitor for adverse reactions of OATP1B1 substrates when coadministered with voclosporin.

• fexofenadine

  voclosporin will increase the level or effect of fexofenadine by Other (see comment). Minor/Significance Unknown. Information suggests voclosporin (an OATP1B1 inhibitor) may increase in the concentration of OATP1B1 substrates is possible. Monitor for adverse reactions of OATP1B1 substrates when coadministered with voclosporin.

• fluvastatin

  voclosporin will increase the level or effect of fluvastatin by Other (see comment). Minor/Significance Unknown. Information suggests voclosporin (an OATP1B1 inhibitor) may increase in the concentration of OATP1B1 substrates is possible. Monitor for adverse reactions of OATP1B1 substrates when coadministered with voclosporin.

• fostamatinib

  fostamatinib will increase the level or effect of voclosporin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown. Reduce voclosporin daily dosage to 15.8 mg PO in AM and 7.9 mg PO in PM.

• glecaprevir/pibrentasvir

  voclosporin will increase the level or effect of glecaprevir/pibrentasvir by Other (see comment). Minor/Significance Unknown. Information suggests voclosporin (an OATP1B1 inhibitor) may increase in the concentration of OATP1B1 substrates is possible. Monitor for adverse reactions of OATP1B1 substrates when coadministered with voclosporin.

• glyburide

  voclosporin will increase the level or effect of glyburide by Other (see comment). Minor/Significance Unknown. Information suggests voclosporin (an OATP1B1 inhibitor) may increase in the concentration of OATP1B1 substrates is possible. Monitor for adverse reactions of OATP1B1 substrates when coadministered with voclosporin.

• letermovir

  voclosporin will increase the level or effect of letermovir by Other (see comment). Minor/Significance Unknown. Information suggests voclosporin (an OATP1B1 inhibitor) may increase in the concentration of OATP1B1 substrates is possible. Monitor for adverse reactions of OATP1B1 substrates when coadministered with voclosporin.

• lovastatin

  voclosporin will increase the level or effect of lovastatin by Other (see comment). Minor/Significance Unknown. Information suggests voclosporin (an OATP1B1 inhibitor) may increase in the concentration of OATP1B1 substrates is possible. Monitor for adverse reactions of OATP1B1 substrates when coadministered with voclosporin.

• methotrexate

  voclosporin will increase the level or effect of methotrexate by Other (see comment). Minor/Significance Unknown. Information suggests voclosporin (an OATP1B1 inhibitor) may increase in the concentration of OATP1B1 substrates is possible. Monitor for adverse reactions of OATP1B1 substrates when coadministered with voclosporin.

• olmesartan

  voclosporin will increase the level or effect of olmesartan by Other (see comment). Minor/Significance Unknown. Information suggests voclosporin (an OATP1B1 inhibitor) may increase in the concentration of OATP1B1 substrates is possible. Monitor for adverse reactions of OATP1B1 substrates when coadministered with voclosporin.

• ombitasvir/paritaprevir/ritonavir

  voclosporin will increase the level or effect of ombitasvir/paritaprevir/ritonavir by Other (see comment). Minor/Significance Unknown. Information suggests voclosporin (an OATP1B1 inhibitor) may increase in the concentration of OATP1B1 substrates is possible. Monitor for adverse reactions of OATP1B1 substrates when coadministered with voclosporin.

• ombitasvir/paritaprevir/ritonavir & dasabuvir (DSC)

  voclosporin will increase the level or effect of ombitasvir/paritaprevir/ritonavir & dasabuvir (DSC) by Other (see comment). Minor/Significance Unknown. Information suggests voclosporin (an OATP1B1 inhibitor) may increase in the concentration of OATP1B1 substrates is possible. Monitor for adverse reactions of OATP1B1 substrates when coadministered with voclosporin.

• pitavastatin

  voclosporin will increase the level or effect of pitavastatin by Other (see comment). Minor/Significance Unknown. Information suggests voclosporin (an OATP1B1 inhibitor) may increase in the concentration of OATP1B1 substrates is possible. Monitor for adverse reactions of OATP1B1 substrates when coadministered with voclosporin.

• pravastatin

  voclosporin will increase the level or effect of pravastatin by Other (see comment). Minor/Significance Unknown. Information suggests voclosporin (an OATP1B1 inhibitor) may increase in the concentration of OATP1B1 substrates is possible. Monitor for adverse reactions of OATP1B1 substrates when coadministered with voclosporin.

• quinupristin/dalfopristin

  quinupristin/dalfopristin will increase the level or effect of voclosporin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown. Reduce voclosporin daily dosage to 15.8 mg PO in AM and 7.9 mg PO in PM.

• repaglinide

  voclosporin will increase the level or effect of repaglinide by Other (see comment). Minor/Significance Unknown. Information suggests voclosporin (an OATP1B1 inhibitor) may increase in the concentration of OATP1B1 substrates is possible. Monitor for adverse reactions of OATP1B1 substrates when coadministered with voclosporin.

• rifamycin

  voclosporin will increase the level or effect of rifamycin by Other (see comment). Minor/Significance Unknown. Information suggests voclosporin (an OATP1B1 inhibitor) may increase in the concentration of OATP1B1 substrates is possible. Monitor for adverse reactions of OATP1B1 substrates when coadministered with voclosporin.

• rosuvastatin

  voclosporin will increase the level or effect of rosuvastatin by Other (see comment). Minor/Significance Unknown. Information suggests voclosporin (an OATP1B1 inhibitor) may increase in the concentration of OATP1B1 substrates is possible. Monitor for adverse reactions of OATP1B1 substrates when coadministered with voclosporin.

• simvastatin

  voclosporin will increase the level or effect of simvastatin by Other (see comment). Minor/Significance Unknown. Information suggests voclosporin (an OATP1B1 inhibitor) may increase in the concentration of OATP1B1 substrates is possible. Monitor for adverse reactions of OATP1B1 substrates when coadministered with voclosporin.

• troglitazone

  voclosporin will increase the level or effect of troglitazone by Other (see comment). Minor/Significance Unknown. Information suggests voclosporin (an OATP1B1 inhibitor) may increase in the concentration of OATP1B1 substrates is possible. Monitor for adverse reactions of OATP1B1 substrates when coadministered with voclosporin.

• valsartan

  voclosporin will increase the level or effect of valsartan by Other (see comment). Minor/Significance Unknown. Information suggests voclosporin (an OATP1B1 inhibitor) may increase in the concentration of OATP1B1 substrates is possible. Monitor for adverse reactions of OATP1B1 substrates when coadministered with voclosporin.

• voxilaprevir

  voclosporin will increase the level or effect of voxilaprevir by Other (see comment). Minor/Significance Unknown. Information suggests voclosporin (an OATP1B1 inhibitor) may increase in the concentration of OATP1B1 substrates is possible. Monitor for adverse reactions of OATP1B1 substrates when coadministered with voclosporin.

• abametapir

  Contraindicated (1)abametapir will increase the level or effect of voclosporin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated.

• adefovir

  Monitor Closely (1)voclosporin, adefovir. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• adenovirus types 4 and 7 live, oral

  Serious - Use Alternative (1)voclosporin decreases effects of adenovirus types 4 and 7 live, oral by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Immunosuppressants also increase risk of infection with concomitant live vaccines. Avoid live vaccines for at least 3 months after immunosuppressants.

• albuterol

  Monitor Closely (1)albuterol and voclosporin both increase QTc interval. Use Caution/Monitor.

• aldesleukin

  Monitor Closely (1)voclosporin, aldesleukin. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• alendronate

  Monitor Closely (1)voclosporin, alendronate. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• alfuzosin

  Monitor Closely (1)voclosporin, alfuzosin. Either increases effects of the other by QTc interval. Use Caution/Monitor.

• aliskiren

  Monitor Closely (2)voclosporin and aliskiren both increase serum potassium. Use Caution/Monitor.
  
  voclosporin, aliskiren. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• ambrisentan

  Minor (1)voclosporin will increase the level or effect of ambrisentan by Other (see comment). Minor/Significance Unknown. Information suggests voclosporin (an OATP1B1 inhibitor) may increase in the concentration of OATP1B1 substrates is possible. Monitor for adverse reactions of OATP1B1 substrates when coadministered with voclosporin.

• amikacin

  Monitor Closely (1)voclosporin, amikacin. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• amikacin liposome inhalation

  Monitor Closely (1)voclosporin, amikacin liposome inhalation. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• amiloride

  Monitor Closely (1)voclosporin and amiloride both increase serum potassium. Use Caution/Monitor.

• aminosalicylic acid

  Monitor Closely (1)voclosporin, aminosalicylic acid. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• amiodarone

  Monitor Closely (2)voclosporin, amiodarone. Either increases effects of the other by QTc interval. Use Caution/Monitor.
  
  amiodarone will increase the level or effect of voclosporin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Reduce voclosporin daily dosage to 15.8 mg PO in AM and 7.9 mg PO in PM.

• amisulpride

  Serious - Use Alternative (1)amisulpride and voclosporin both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.

• amitriptyline

  Monitor Closely (1)voclosporin, amitriptyline. Either increases effects of the other by QTc interval. Use Caution/Monitor.

• amobarbital

  Serious - Use Alternative (1)amobarbital will decrease the level or effect of voclosporin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.

• amoxapine

  Monitor Closely (1)voclosporin, amoxapine. Either increases effects of the other by QTc interval. Use Caution/Monitor.

• amphotericin B cholesteryl sulfate

  Monitor Closely (1)voclosporin, amphotericin B cholesteryl sulfate. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• amphotericin B deoxycholate

  Monitor Closely (1)voclosporin, amphotericin B deoxycholate. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• amphotericin B liposomal

  Monitor Closely (1)voclosporin, amphotericin B liposomal. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• amphotericin B phospholipid complex

  Monitor Closely (1)voclosporin, amphotericin B phospholipid complex. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• anagrelide

  Serious - Use Alternative (1)anagrelide and voclosporin both increase QTc interval. Avoid or Use Alternate Drug.

• anidulafungin

  Monitor Closely (1)voclosporin, anidulafungin. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• anthrax vaccine adsorbed

  Monitor Closely (1)voclosporin decreases effects of anthrax vaccine adsorbed by immunosuppressive effects; risk of infection. Modify Therapy/Monitor Closely. Inactivated vaccines noted to be safe for administration may not be sufficiently immunogenic during treatment.

• apalutamide

  Serious - Use Alternative (1)apalutamide will decrease the level or effect of voclosporin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.

• apomorphine

  Monitor Closely (1)voclosporin, apomorphine. Either increases effects of the other by QTc interval. Use Caution/Monitor.

• aprepitant

  Monitor Closely (1)aprepitant will increase the level or effect of voclosporin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Reduce voclosporin daily dosage to 15.8 mg PO in AM and 7.9 mg PO in PM.

• arformoterol

  Monitor Closely (1)voclosporin, arformoterol. Either increases effects of the other by QTc interval. Use Caution/Monitor.

• aripiprazole

  Monitor Closely (1)aripiprazole and voclosporin both increase QTc interval. Use Caution/Monitor.

• armodafinil

  Serious - Use Alternative (1)armodafinil will decrease the level or effect of voclosporin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.

• arsenic trioxide

  Monitor Closely (1)voclosporin, arsenic trioxide. Either increases effects of the other by QTc interval. Use Caution/Monitor.

• artemether

  Serious - Use Alternative (1)artemether and voclosporin both increase QTc interval. Avoid or Use Alternate Drug.

• artemether/lumefantrine

  Monitor Closely (1)voclosporin, artemether/lumefantrine. Either increases effects of the other by QTc interval. Use Caution/Monitor.

• asenapine

  Monitor Closely (1)voclosporin, asenapine. Either increases effects of the other by QTc interval. Use Caution/Monitor.

• asenapine transdermal

  Monitor Closely (1)voclosporin, asenapine transdermal. Either increases effects of the other by QTc interval. Use Caution/Monitor.

• aspirin

  Monitor Closely (1)voclosporin, aspirin. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• aspirin rectal

  Monitor Closely (1)voclosporin, aspirin rectal. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• atazanavir

  Contraindicated (1)atazanavir will increase the level or effect of voclosporin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated.

• atomoxetine

  Monitor Closely (1)atomoxetine and voclosporin both increase QTc interval. Use Caution/Monitor.

• atorvastatin

  Minor (1)voclosporin will increase the level or effect of atorvastatin by Other (see comment). Minor/Significance Unknown. Information suggests voclosporin (an OATP1B1 inhibitor) may increase in the concentration of OATP1B1 substrates is possible. Monitor for adverse reactions of OATP1B1 substrates when coadministered with voclosporin.

• axicabtagene ciloleucel

  Serious - Use Alternative (1)voclosporin, axicabtagene ciloleucel. Either increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug.

• azilsartan

  Monitor Closely (2)voclosporin and azilsartan both increase serum potassium. Use Caution/Monitor.
  
  voclosporin, azilsartan. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• azithromycin

  Monitor Closely (1)voclosporin, azithromycin. Either increases effects of the other by QTc interval. Use Caution/Monitor.

• balsalazide

  Monitor Closely (1)voclosporin, balsalazide. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• BCG vaccine live

  Serious - Use Alternative (1)voclosporin decreases effects of BCG vaccine live by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Immunosuppressants also increase risk of infection with concomitant live vaccines. Avoid live vaccines for at least 3 months after immunosuppressants.

• bedaquiline

  Monitor Closely (1)voclosporin, bedaquiline. Either increases effects of the other by QTc interval. Use Caution/Monitor.

• benazepril

  Monitor Closely (2)voclosporin and benazepril both increase serum potassium. Use Caution/Monitor.
  
  voclosporin, benazepril. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• berotralstat

  Monitor Closely (1)berotralstat will increase the level or effect of voclosporin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Reduce voclosporin daily dosage to 15.8 mg PO in AM and 7.9 mg PO in PM.

• bexarotene

  Serious - Use Alternative (1)bexarotene will decrease the level or effect of voclosporin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.

• bicalutamide

  Monitor Closely (1)bicalutamide will increase the level or effect of voclosporin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Reduce voclosporin daily dosage to 15.8 mg PO in AM and 7.9 mg PO in PM.

• bosentan

  Serious - Use Alternative (1)bosentan will decrease the level or effect of voclosporin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.Minor (1)voclosporin will increase the level or effect of bosentan by Other (see comment). Minor/Significance Unknown. Information suggests voclosporin (an OATP1B1 inhibitor) may increase in the concentration of OATP1B1 substrates is possible. Monitor for adverse reactions of OATP1B1 substrates when coadministered with voclosporin.

• bosutinib

  Monitor Closely (1)bosutinib and voclosporin both increase QTc interval. Use Caution/Monitor.

• brexucabtagene autoleucel

  Serious - Use Alternative (1)voclosporin, brexucabtagene autoleucel. Either increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug.

• brigatinib

  Serious - Use Alternative (1)brigatinib will decrease the level or effect of voclosporin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.

• buprenorphine

  Serious - Use Alternative (1)buprenorphine and voclosporin both increase QTc interval. Avoid or Use Alternate Drug.

• buprenorphine buccal

  Serious - Use Alternative (1)buprenorphine buccal and voclosporin both increase QTc interval. Avoid or Use Alternate Drug.

• buprenorphine subdermal implant

  Serious - Use Alternative (1)buprenorphine subdermal implant and voclosporin both increase QTc interval. Avoid or Use Alternate Drug.

• buprenorphine transdermal

  Serious - Use Alternative (1)buprenorphine transdermal and voclosporin both increase QTc interval. Avoid or Use Alternate Drug.

• buprenorphine, long-acting injection

  Serious - Use Alternative (1)buprenorphine, long-acting injection and voclosporin both increase QTc interval. Avoid or Use Alternate Drug.

• butabarbital

  Serious - Use Alternative (1)butabarbital will decrease the level or effect of voclosporin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.

• butalbital

  Serious - Use Alternative (1)butalbital will decrease the level or effect of voclosporin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.

• canagliflozin

  Monitor Closely (1)voclosporin and canagliflozin both increase serum potassium. Use Caution/Monitor.

• candesartan

  Monitor Closely (2)voclosporin and candesartan both increase serum potassium. Use Caution/Monitor.
  
  voclosporin, candesartan. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• capecitabine

  Monitor Closely (1)capecitabine and voclosporin both increase QTc interval. Use Caution/Monitor.

• capreomycin

  Monitor Closely (1)voclosporin, capreomycin. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• captopril

  Monitor Closely (2)voclosporin and captopril both increase serum potassium. Use Caution/Monitor.
  
  voclosporin, captopril. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• carbamazepine

  Serious - Use Alternative (1)carbamazepine will decrease the level or effect of voclosporin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.

• carboplatin

  Monitor Closely (1)voclosporin, carboplatin. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• caspofungin

  Monitor Closely (1)voclosporin, caspofungin. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.Minor (1)voclosporin will increase the level or effect of caspofungin by Other (see comment). Minor/Significance Unknown. Information suggests voclosporin (an OATP1B1 inhibitor) may increase in the concentration of OATP1B1 substrates is possible. Monitor for adverse reactions of OATP1B1 substrates when coadministered with voclosporin.

• cefaclor

  Monitor Closely (1)voclosporin, cefaclor. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• cefadroxil

  Monitor Closely (1)voclosporin, cefadroxil. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• cefazolin

  Monitor Closely (1)voclosporin, cefazolin. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• cefdinir

  Monitor Closely (1)voclosporin, cefdinir. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• cefditoren

  Monitor Closely (1)voclosporin, cefditoren. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• cefixime

  Monitor Closely (1)voclosporin, cefixime. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• cefotaxime

  Monitor Closely (1)voclosporin, cefotaxime. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• cefotetan

  Monitor Closely (1)voclosporin, cefotetan. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• cefoxitin

  Monitor Closely (1)voclosporin, cefoxitin. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• cefpodoxime

  Monitor Closely (1)voclosporin, cefpodoxime. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• cefprozil

  Monitor Closely (1)voclosporin, cefprozil. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• ceftazidime

  Monitor Closely (1)voclosporin, ceftazidime. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• ceftazidime/avibactam

  Monitor Closely (1)voclosporin, ceftazidime/avibactam. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• ceftibuten

  Monitor Closely (1)voclosporin, ceftibuten. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• ceftizoxime

  Monitor Closely (1)voclosporin, ceftizoxime. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• ceftriaxone

  Monitor Closely (1)voclosporin, ceftriaxone. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• cefuroxime

  Monitor Closely (1)voclosporin, cefuroxime. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• celecoxib

  Monitor Closely (1)voclosporin, celecoxib. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• cephalexin

  Monitor Closely (1)voclosporin, cephalexin. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• ceritinib

  Contraindicated (1)ceritinib and voclosporin both increase QTc interval. Contraindicated.Monitor Closely (1)ceritinib will increase the level or effect of voclosporin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Reduce voclosporin daily dosage to 15.8 mg PO in AM and 7.9 mg PO in PM.

• chloramphenicol

  Contraindicated (1)chloramphenicol will increase the level or effect of voclosporin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated.

• chloroquine

  Serious - Use Alternative (1)chloroquine and voclosporin both increase QTc interval. Avoid or Use Alternate Drug.

• chlorpromazine

  Monitor Closely (1)voclosporin, chlorpromazine. Either increases effects of the other by QTc interval. Use Caution/Monitor.

• cholera vaccine

  Serious - Use Alternative (1)voclosporin decreases effects of cholera vaccine by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Immunosuppressants also increase risk of infection with concomitant live vaccines. Avoid live vaccines for at least 3 months after immunosuppressants.

• choline magnesium trisalicylate

  Monitor Closely (1)voclosporin, choline magnesium trisalicylate. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• cidofovir

  Monitor Closely (1)voclosporin, cidofovir. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• ciltacabtagene autoleucel

  Serious - Use Alternative (1)voclosporin, ciltacabtagene autoleucel. Either increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug.

• ciprofloxacin

  Monitor Closely (1)voclosporin, ciprofloxacin. Either increases effects of the other by QTc interval. Use Caution/Monitor.

• cisplatin

  Monitor Closely (1)voclosporin, cisplatin. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• citalopram

  Monitor Closely (1)voclosporin, citalopram. Either increases effects of the other by QTc interval. Use Caution/Monitor.

• clarithromycin

  Contraindicated (1)clarithromycin will increase the level or effect of voclosporin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated.Monitor Closely (1)voclosporin, clarithromycin. Either increases effects of the other by QTc interval. Use Caution/Monitor.

• clobazam

  Serious - Use Alternative (1)clobazam will decrease the level or effect of voclosporin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.

• clofazimine

  Monitor Closely (1)voclosporin, clofazimine. Either increases effects of the other by QTc interval. Use Caution/Monitor.

• clomipramine

  Monitor Closely (1)voclosporin, clomipramine. Either increases effects of the other by QTc interval. Use Caution/Monitor.

• clonidine

  Monitor Closely (1)voclosporin will increase the level or effect of clonidine by P-glycoprotein (MDR1) efflux transporter. Modify Therapy/Monitor Closely. Coadministration of voclosporin (a P-gp inhibitor) increases exposure and risk of adverse reactions of P-gp substrates. For certain P-gp substrates with a narrow therapeutic window, refer to prescribing information of these substrates for dosage modifications, if needed.

• clotrimazole

  Monitor Closely (1)clotrimazole will increase the level or effect of voclosporin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Reduce voclosporin daily dosage to 15.8 mg PO in AM and 7.9 mg PO in PM.

• clozapine

  Monitor Closely (1)voclosporin, clozapine. Either increases effects of the other by QTc interval. Use Caution/Monitor.

• cobicistat

  Contraindicated (1)cobicistat will increase the level or effect of voclosporin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated.

• colchicine

  Monitor Closely (1)voclosporin will increase the level or effect of colchicine by P-glycoprotein (MDR1) efflux transporter. Modify Therapy/Monitor Closely. Coadministration of voclosporin (a P-gp inhibitor) increases exposure and risk of adverse reactions of P-gp substrates. For certain P-gp substrates with a narrow therapeutic window, refer to prescribing information of these substrates for dosage modifications, if needed.

• colistin

  Monitor Closely (1)voclosporin, colistin. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• conivaptan

  Contraindicated (1)conivaptan will increase the level or effect of voclosporin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated.

• COVID-19 vaccine, adjuvanted-Novavax

  Monitor Closely (1)voclosporin decreases effects of COVID-19 vaccine, adjuvanted-Novavax by immunosuppressive effects; risk of infection. Modify Therapy/Monitor Closely. Inactivated vaccines noted to be safe for administration may not be sufficiently immunogenic during treatment.

• COVID-19 vaccine, mRNA-Pfizer

  Monitor Closely (1)voclosporin decreases effects of COVID-19 vaccine, mRNA-Pfizer by immunosuppressive effects; risk of infection. Modify Therapy/Monitor Closely. Inactivated vaccines noted to be safe for administration may not be sufficiently immunogenic during treatment.

• COVID-19 vaccine, viral vector-Janssen

  Monitor Closely (1)voclosporin decreases effects of COVID-19 vaccine, viral vector-Janssen by immunosuppressive effects; risk of infection. Modify Therapy/Monitor Closely. Inactivated vaccines noted to be safe for administration may not be sufficiently immunogenic during treatment.

• crizotinib

  Monitor Closely (2)voclosporin, crizotinib. Either increases effects of the other by QTc interval. Use Caution/Monitor.
  
  crizotinib will increase the level or effect of voclosporin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Reduce voclosporin daily dosage to 15.8 mg PO in AM and 7.9 mg PO in PM.

• cyclophosphamide

  Monitor Closely (1)voclosporin, cyclophosphamide. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• cyclosporine

  Monitor Closely (2)voclosporin and cyclosporine both increase serum potassium. Use Caution/Monitor.
  
  cyclosporine will increase the level or effect of voclosporin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Reduce voclosporin daily dosage to 15.8 mg PO in AM and 7.9 mg PO in PM.

• dabrafenib

  Serious - Use Alternative (1)dabrafenib will decrease the level or effect of voclosporin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.

• darunavir

  Contraindicated (1)darunavir will increase the level or effect of voclosporin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated.

• dasatinib

  Monitor Closely (1)voclosporin, dasatinib. Either increases effects of the other by QTc interval. Use Caution/Monitor.

• degarelix

  Monitor Closely (1)voclosporin, degarelix. Either increases effects of the other by QTc interval. Use Caution/Monitor.

• dengue vaccine

  Serious - Use Alternative (1)voclosporin decreases effects of dengue vaccine by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Immunosuppressants also increase risk of infection with concomitant live vaccines. Avoid live vaccines for at least 3 months after immunosuppressants.

• desflurane

  Serious - Use Alternative (1)desflurane and voclosporin both increase QTc interval. Avoid or Use Alternate Drug.

• desipramine

  Monitor Closely (1)voclosporin, desipramine. Either increases effects of the other by QTc interval. Use Caution/Monitor.

• deutetrabenazine

  Monitor Closely (1)voclosporin, deutetrabenazine. Either increases effects of the other by QTc interval. Use Caution/Monitor. At the maximum recommended dose, deutetrabenazine does not prolong QT interval to a clinically relevant extent. Certain circumstances may increase risk of torsade de pointes and/or sudden death in association with drugs that prolong the QTc interval (eg, bradycardia, hypokalemia or hypomagnesemia, coadministration with other drugs that prolong QTc interval, presence of congenital QT prolongation).

• diatrizoate

  Monitor Closely (1)voclosporin, diatrizoate. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• diatrizoate meglumine/diatrizoate sodium

  Monitor Closely (1)voclosporin, diatrizoate meglumine/diatrizoate sodium. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• diclofenac

  Monitor Closely (1)voclosporin, diclofenac. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• diflunisal

  Monitor Closely (1)voclosporin, diflunisal. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• diltiazem

  Monitor Closely (1)diltiazem will increase the level or effect of voclosporin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Reduce voclosporin daily dosage to 15.8 mg PO in AM and 7.9 mg PO in PM.

• disopyramide

  Monitor Closely (1)voclosporin, disopyramide. Either increases effects of the other by QTc interval. Use Caution/Monitor.

• dofetilide

  Monitor Closely (1)voclosporin, dofetilide. Either increases effects of the other by QTc interval. Use Caution/Monitor.

• dolasetron

  Monitor Closely (1)voclosporin, dolasetron. Either increases effects of the other by QTc interval. Use Caution/Monitor.

• donepezil

  Monitor Closely (1)donepezil and voclosporin both increase QTc interval. Use Caution/Monitor.

• doxepin

  Monitor Closely (1)doxepin and voclosporin both increase QTc interval. Use Caution/Monitor.

• doxycycline

  Monitor Closely (1)doxycycline will increase the level or effect of voclosporin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Reduce voclosporin daily dosage to 15.8 mg PO in AM and 7.9 mg PO in PM.

• dronedarone

  Monitor Closely (2)voclosporin, dronedarone. Either increases effects of the other by QTc interval. Use Caution/Monitor.
  
  dronedarone will increase the level or effect of voclosporin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Reduce voclosporin daily dosage to 15.8 mg PO in AM and 7.9 mg PO in PM.

• droperidol

  Monitor Closely (1)voclosporin, droperidol. Either increases effects of the other by QTc interval. Use Caution/Monitor.

• drospirenone

  Monitor Closely (1)voclosporin and drospirenone both increase serum potassium. Use Caution/Monitor.

• Ebola Zaire vaccine

  Serious - Use Alternative (1)voclosporin decreases effects of Ebola Zaire vaccine by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Immunosuppressants also increase risk of infection with concomitant live vaccines. Avoid live vaccines for at least 3 months after immunosuppressants.

• efavirenz

  Serious - Use Alternative (2)efavirenz will decrease the level or effect of voclosporin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.
  
  efavirenz and voclosporin both increase QTc interval. Avoid or Use Alternate Drug.

• elagolix

  Serious - Use Alternative (1)elagolix will decrease the level or effect of voclosporin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.Minor (1)voclosporin will increase the level or effect of elagolix by Other (see comment). Minor/Significance Unknown. Information suggests voclosporin (an OATP1B1 inhibitor) may increase in the concentration of OATP1B1 substrates is possible. Monitor for adverse reactions of OATP1B1 substrates when coadministered with voclosporin.

• elbasvir/grazoprevir

  Minor (1)voclosporin will increase the level or effect of elbasvir/grazoprevir by Other (see comment). Minor/Significance Unknown. Information suggests voclosporin (an OATP1B1 inhibitor) may increase in the concentration of OATP1B1 substrates is possible. Monitor for adverse reactions of OATP1B1 substrates when coadministered with voclosporin.

• eliglustat

  Monitor Closely (1)eliglustat and voclosporin both increase QTc interval. Use Caution/Monitor.

• eluxadoline

  Minor (1)voclosporin will increase the level or effect of eluxadoline by Other (see comment). Minor/Significance Unknown. Information suggests voclosporin (an OATP1B1 inhibitor) may increase in the concentration of OATP1B1 substrates is possible. Monitor for adverse reactions of OATP1B1 substrates when coadministered with voclosporin.

• elvitegravir

  Monitor Closely (1)voclosporin, elvitegravir. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• elvitegravir/cobicistat/emtricitabine/tenofovir DF

  Contraindicated (1)elvitegravir/cobicistat/emtricitabine/tenofovir DF will increase the level or effect of voclosporin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated.

• enalapril

  Monitor Closely (2)voclosporin and enalapril both increase serum potassium. Use Caution/Monitor.
  
  voclosporin, enalapril. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.Minor (1)voclosporin will increase the level or effect of enalapril by Other (see comment). Minor/Significance Unknown. Information suggests voclosporin (an OATP1B1 inhibitor) may increase in the concentration of OATP1B1 substrates is possible. Monitor for adverse reactions of OATP1B1 substrates when coadministered with voclosporin.

• encorafenib

  Monitor Closely (1)voclosporin, encorafenib. Either increases effects of the other by QTc interval. Use Caution/Monitor.Serious - Use Alternative (1)encorafenib will decrease the level or effect of voclosporin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.

• entacapone

  Monitor Closely (1)entacapone will increase the level or effect of voclosporin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Reduce voclosporin daily dosage to 15.8 mg PO in AM and 7.9 mg PO in PM.

• entrectinib

  Monitor Closely (1)voclosporin, entrectinib. Either increases effects of the other by QTc interval. Use Caution/Monitor.

• enzalutamide

  Serious - Use Alternative (1)enzalutamide will decrease the level or effect of voclosporin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.

• eplerenone

  Monitor Closely (1)voclosporin and eplerenone both increase serum potassium. Use Caution/Monitor.

• eprosartan

  Monitor Closely (2)voclosporin and eprosartan both increase serum potassium. Use Caution/Monitor.
  
  voclosporin, eprosartan. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• eribulin

  Monitor Closely (1)voclosporin, eribulin. Either increases effects of the other by QTc interval. Use Caution/Monitor.

• erythromycin base

  Monitor Closely (2)voclosporin, erythromycin base. Either increases effects of the other by QTc interval. Use Caution/Monitor.
  
  erythromycin base will increase the level or effect of voclosporin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Reduce voclosporin daily dosage to 15.8 mg PO in AM and 7.9 mg PO in PM.

• erythromycin ethylsuccinate

  Monitor Closely (2)voclosporin, erythromycin ethylsuccinate. Either increases effects of the other by QTc interval. Use Caution/Monitor.
  
  erythromycin ethylsuccinate will increase the level or effect of voclosporin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Reduce voclosporin daily dosage to 15.8 mg PO in AM and 7.9 mg PO in PM.

• erythromycin lactobionate

  Monitor Closely (2)voclosporin, erythromycin lactobionate. Either increases effects of the other by QTc interval. Use Caution/Monitor.
  
  erythromycin lactobionate will increase the level or effect of voclosporin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Reduce voclosporin daily dosage to 15.8 mg PO in AM and 7.9 mg PO in PM.

• erythromycin stearate

  Monitor Closely (2)voclosporin, erythromycin stearate. Either increases effects of the other by QTc interval. Use Caution/Monitor.
  
  erythromycin stearate will increase the level or effect of voclosporin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Reduce voclosporin daily dosage to 15.8 mg PO in AM and 7.9 mg PO in PM.

• escitalopram

  Monitor Closely (1)voclosporin, escitalopram. Either increases effects of the other by QTc interval. Use Caution/Monitor.

• eslicarbazepine acetate

  Serious - Use Alternative (1)eslicarbazepine acetate will decrease the level or effect of voclosporin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.

• ethiodized oil

  Monitor Closely (1)voclosporin, ethiodized oil. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• etidronate

  Monitor Closely (1)voclosporin, etidronate. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• etodolac

  Monitor Closely (1)voclosporin, etodolac. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• etravirine

  Serious - Use Alternative (1)etravirine will decrease the level or effect of voclosporin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.

• everolimus

  Monitor Closely (1)voclosporin, everolimus. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• ezetimibe

  Minor (1)voclosporin will increase the level or effect of ezetimibe by Other (see comment). Minor/Significance Unknown. Information suggests voclosporin (an OATP1B1 inhibitor) may increase in the concentration of OATP1B1 substrates is possible. Monitor for adverse reactions of OATP1B1 substrates when coadministered with voclosporin.

• ezogabine

  Monitor Closely (1)voclosporin, ezogabine. Either increases effects of the other by QTc interval. Use Caution/Monitor.

• fedratinib

  Monitor Closely (1)fedratinib will increase the level or effect of voclosporin by affecting hepatic enzyme CYP2E1 metabolism. Modify Therapy/Monitor Closely. Reduce voclosporin daily dosage to 15.8 mg PO in AM and 7.9 mg PO in PM.

• fenoprofen

  Monitor Closely (1)voclosporin, fenoprofen. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• fexofenadine

  Minor (1)voclosporin will increase the level or effect of fexofenadine by Other (see comment). Minor/Significance Unknown. Information suggests voclosporin (an OATP1B1 inhibitor) may increase in the concentration of OATP1B1 substrates is possible. Monitor for adverse reactions of OATP1B1 substrates when coadministered with voclosporin.

• finerenone

  Monitor Closely (1)voclosporin and finerenone both increase serum potassium. Use Caution/Monitor.

• fingolimod

  Monitor Closely (1)fingolimod and voclosporin both increase QTc interval. Use Caution/Monitor.

• flecainide

  Monitor Closely (1)voclosporin, flecainide. Either increases effects of the other by QTc interval. Use Caution/Monitor.

• fluconazole

  Monitor Closely (3)voclosporin, fluconazole. Either increases effects of the other by QTc interval. Use Caution/Monitor.
  
  fluconazole will increase the level or effect of voclosporin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Reduce voclosporin daily dosage to 15.8 mg PO in AM and 7.9 mg PO in PM.
  
  voclosporin, fluconazole. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• flucytosine

  Monitor Closely (1)voclosporin, flucytosine. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• fluoxetine

  Monitor Closely (1)voclosporin, fluoxetine. Either increases effects of the other by QTc interval. Use Caution/Monitor.

• flurbiprofen

  Monitor Closely (1)voclosporin, flurbiprofen. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• fluvastatin

  Minor (1)voclosporin will increase the level or effect of fluvastatin by Other (see comment). Minor/Significance Unknown. Information suggests voclosporin (an OATP1B1 inhibitor) may increase in the concentration of OATP1B1 substrates is possible. Monitor for adverse reactions of OATP1B1 substrates when coadministered with voclosporin.

• fluvoxamine

  Monitor Closely (1)fluvoxamine will increase the level or effect of voclosporin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Reduce voclosporin daily dosage to 15.8 mg PO in AM and 7.9 mg PO in PM.

• fosamprenavir

  Monitor Closely (1)fosamprenavir will increase the level or effect of voclosporin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Reduce voclosporin daily dosage to 15.8 mg PO in AM and 7.9 mg PO in PM.

• fosaprepitant

  Monitor Closely (1)fosaprepitant will increase the level or effect of voclosporin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Reduce voclosporin daily dosage to 15.8 mg PO in AM and 7.9 mg PO in PM.

• foscarnet

  Monitor Closely (1)voclosporin, foscarnet. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• fosinopril

  Monitor Closely (2)voclosporin and fosinopril both increase serum potassium. Use Caution/Monitor.
  
  voclosporin, fosinopril. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• fostamatinib

  Minor (1)fostamatinib will increase the level or effect of voclosporin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown. Reduce voclosporin daily dosage to 15.8 mg PO in AM and 7.9 mg PO in PM.

• gadobenate

  Monitor Closely (1)voclosporin, gadobenate. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• gadobutrol

  Monitor Closely (1)voclosporin, gadobutrol. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• gadodiamide

  Monitor Closely (1)voclosporin, gadodiamide. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• gadofosveset

  Monitor Closely (1)voclosporin, gadofosveset. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• gadopentetate

  Monitor Closely (1)voclosporin, gadopentetate. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• gadoterate meglumine

  Monitor Closely (1)voclosporin, gadoterate meglumine. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• gadoteridol

  Monitor Closely (1)voclosporin, gadoteridol. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• gadoversetamide

  Monitor Closely (1)voclosporin, gadoversetamide. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• gadoxetate

  Monitor Closely (1)voclosporin, gadoxetate. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• ganciclovir

  Monitor Closely (1)voclosporin, ganciclovir. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• gemifloxacin

  Monitor Closely (1)gemifloxacin and voclosporin both increase QTc interval. Use Caution/Monitor.

• gemtuzumab

  Monitor Closely (1)voclosporin, gemtuzumab. Either increases effects of the other by QTc interval. Use Caution/Monitor.

• gentamicin

  Monitor Closely (1)voclosporin, gentamicin. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• gilteritinib

  Monitor Closely (1)gilteritinib and voclosporin both increase QTc interval. Use Caution/Monitor.

• glasdegib

  Monitor Closely (1)voclosporin, glasdegib. Either increases effects of the other by QTc interval. Use Caution/Monitor.

• glecaprevir/pibrentasvir

  Minor (1)voclosporin will increase the level or effect of glecaprevir/pibrentasvir by Other (see comment). Minor/Significance Unknown. Information suggests voclosporin (an OATP1B1 inhibitor) may increase in the concentration of OATP1B1 substrates is possible. Monitor for adverse reactions of OATP1B1 substrates when coadministered with voclosporin.

• glyburide

  Minor (1)voclosporin will increase the level or effect of glyburide by Other (see comment). Minor/Significance Unknown. Information suggests voclosporin (an OATP1B1 inhibitor) may increase in the concentration of OATP1B1 substrates is possible. Monitor for adverse reactions of OATP1B1 substrates when coadministered with voclosporin.

• granisetron

  Monitor Closely (1)granisetron and voclosporin both increase QTc interval. Use Caution/Monitor.

• grapefruit

  Contraindicated (1)grapefruit will increase the level or effect of voclosporin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated.

• griseofulvin

  Monitor Closely (1)voclosporin, griseofulvin. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• haemophilus influenzae type b vaccine

  Monitor Closely (1)voclosporin decreases effects of haemophilus influenzae type b vaccine by immunosuppressive effects; risk of infection. Modify Therapy/Monitor Closely. Inactivated vaccines noted to be safe for administration may not be sufficiently immunogenic during treatment.

• haloperidol

  Monitor Closely (2)voclosporin, haloperidol. Either increases effects of the other by QTc interval. Use Caution/Monitor.
  
  haloperidol will increase the level or effect of voclosporin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Reduce voclosporin daily dosage to 15.8 mg PO in AM and 7.9 mg PO in PM.

• heparin

  Monitor Closely (1)voclosporin and heparin both increase serum potassium. Use Caution/Monitor.

• hepatitis A vaccine inactivated

  Monitor Closely (1)voclosporin decreases effects of hepatitis A vaccine inactivated by immunosuppressive effects; risk of infection. Modify Therapy/Monitor Closely. Inactivated vaccines noted to be safe for administration may not be sufficiently immunogenic during treatment.

• hepatitis a/b vaccine

  Monitor Closely (1)voclosporin decreases effects of hepatitis a/b vaccine by immunosuppressive effects; risk of infection. Modify Therapy/Monitor Closely. Inactivated vaccines noted to be safe for administration may not be sufficiently immunogenic during treatment.

• hepatitis b vaccine

  Monitor Closely (1)voclosporin decreases effects of hepatitis b vaccine by immunosuppressive effects; risk of infection. Modify Therapy/Monitor Closely. Inactivated vaccines noted to be safe for administration may not be sufficiently immunogenic during treatment.

• HIV vaccine

  Monitor Closely (1)voclosporin decreases effects of HIV vaccine by immunosuppressive effects; risk of infection. Modify Therapy/Monitor Closely. Inactivated vaccines noted to be safe for administration may not be sufficiently immunogenic during treatment.

• human papillomavirus vaccine, bivalent

  Monitor Closely (1)voclosporin decreases effects of human papillomavirus vaccine, bivalent by immunosuppressive effects; risk of infection. Modify Therapy/Monitor Closely. Inactivated vaccines noted to be safe for administration may not be sufficiently immunogenic during treatment.

• human papillomavirus vaccine, nonavalent

  Monitor Closely (1)voclosporin decreases effects of human papillomavirus vaccine, nonavalent by immunosuppressive effects; risk of infection. Modify Therapy/Monitor Closely. Inactivated vaccines noted to be safe for administration may not be sufficiently immunogenic during treatment.

• human papillomavirus vaccine, quadrivalent

  Monitor Closely (1)voclosporin decreases effects of human papillomavirus vaccine, quadrivalent by immunosuppressive effects; risk of infection. Modify Therapy/Monitor Closely. Inactivated vaccines noted to be safe for administration may not be sufficiently immunogenic during treatment.

• hydroxychloroquine sulfate

  Monitor Closely (1)voclosporin, hydroxychloroquine sulfate. Either increases effects of the other by QTc interval. Use Caution/Monitor.

• hydroxyzine

  Monitor Closely (1)hydroxyzine and voclosporin both increase QTc interval. Use Caution/Monitor.

• ibandronate

  Monitor Closely (1)voclosporin, ibandronate. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• ibrexafungerp

  Monitor Closely (1)voclosporin, ibrexafungerp. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• ibuprofen

  Monitor Closely (1)voclosporin, ibuprofen. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• ibuprofen IV

  Monitor Closely (1)voclosporin, ibuprofen IV. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• ibuprofen/famotidine

  Monitor Closely (1)voclosporin, ibuprofen/famotidine. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• ibutilide

  Monitor Closely (1)voclosporin, ibutilide. Either increases effects of the other by QTc interval. Use Caution/Monitor.

• idecabtagene vicleucel

  Serious - Use Alternative (1)voclosporin, idecabtagene vicleucel. Either increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug.

• idelalisib

  Contraindicated (1)idelalisib will increase the level or effect of voclosporin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated.

• ifosfamide

  Monitor Closely (1)voclosporin, ifosfamide. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• iloperidone

  Monitor Closely (2)voclosporin, iloperidone. Either increases effects of the other by QTc interval. Use Caution/Monitor.
  
  iloperidone will increase the level or effect of voclosporin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Reduce voclosporin daily dosage to 15.8 mg PO in AM and 7.9 mg PO in PM.

• imatinib

  Monitor Closely (1)imatinib will increase the level or effect of voclosporin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Reduce voclosporin daily dosage to 15.8 mg PO in AM and 7.9 mg PO in PM.

• indacaterol, inhaled

  Monitor Closely (1)voclosporin, indacaterol, inhaled. Either increases effects of the other by QTc interval. Use Caution/Monitor.

• indapamide

  Monitor Closely (1)voclosporin, indapamide. Either increases effects of the other by QTc interval. Use Caution/Monitor.

• indinavir

  Contraindicated (1)indinavir will increase the level or effect of voclosporin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated.

• indomethacin

  Monitor Closely (1)voclosporin, indomethacin. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• influenza A (H5N1) vaccine

  Monitor Closely (1)voclosporin decreases effects of influenza A (H5N1) vaccine by immunosuppressive effects; risk of infection. Modify Therapy/Monitor Closely. Inactivated vaccines noted to be safe for administration may not be sufficiently immunogenic during treatment.

• influenza virus vaccine (H5N1), adjuvanted

  Monitor Closely (1)voclosporin decreases effects of influenza virus vaccine (H5N1), adjuvanted by immunosuppressive effects; risk of infection. Modify Therapy/Monitor Closely. Inactivated vaccines noted to be safe for administration may not be sufficiently immunogenic during treatment.

• influenza virus vaccine quadrivalent

  Monitor Closely (1)voclosporin decreases effects of influenza virus vaccine quadrivalent by immunosuppressive effects; risk of infection. Modify Therapy/Monitor Closely. Inactivated vaccines noted to be safe for administration may not be sufficiently immunogenic during treatment.

• influenza virus vaccine quadrivalent, adjuvanted

  Monitor Closely (1)voclosporin decreases effects of influenza virus vaccine quadrivalent, adjuvanted by immunosuppressive effects; risk of infection. Modify Therapy/Monitor Closely. Inactivated vaccines noted to be safe for administration may not be sufficiently immunogenic during treatment.

• influenza virus vaccine quadrivalent, cell-cultured

  Monitor Closely (1)voclosporin decreases effects of influenza virus vaccine quadrivalent, cell-cultured by immunosuppressive effects; risk of infection. Modify Therapy/Monitor Closely. Inactivated vaccines noted to be safe for administration may not be sufficiently immunogenic during treatment.

• influenza virus vaccine quadrivalent, intranasal

  Serious - Use Alternative (1)voclosporin decreases effects of influenza virus vaccine quadrivalent, intranasal by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Immunosuppressants also increase risk of infection with concomitant live vaccines. Avoid live vaccines for at least 3 months after immunosuppressants.

• influenza virus vaccine quadrivalent, recombinant

  Monitor Closely (1)voclosporin decreases effects of influenza virus vaccine quadrivalent, recombinant by immunosuppressive effects; risk of infection. Modify Therapy/Monitor Closely. Inactivated vaccines noted to be safe for administration may not be sufficiently immunogenic during treatment.

• influenza virus vaccine trivalent

  Monitor Closely (1)voclosporin decreases effects of influenza virus vaccine trivalent by immunosuppressive effects; risk of infection. Modify Therapy/Monitor Closely. Inactivated vaccines noted to be safe for administration may not be sufficiently immunogenic during treatment.

• influenza virus vaccine trivalent, adjuvanted

  Monitor Closely (1)voclosporin decreases effects of influenza virus vaccine trivalent, adjuvanted by immunosuppressive effects; risk of infection. Modify Therapy/Monitor Closely. Inactivated vaccines noted to be safe for administration may not be sufficiently immunogenic during treatment.

• influenza virus vaccine trivalent, recombinant

  Monitor Closely (1)voclosporin decreases effects of influenza virus vaccine trivalent, recombinant by immunosuppressive effects; risk of infection. Modify Therapy/Monitor Closely. Inactivated vaccines noted to be safe for administration may not be sufficiently immunogenic during treatment.

• inotersen

  Monitor Closely (1)voclosporin, inotersen. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• inotuzumab

  Monitor Closely (1)voclosporin, inotuzumab. Either increases effects of the other by QTc interval. Use Caution/Monitor.

• iodixanol

  Monitor Closely (1)voclosporin, iodixanol. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• ioflupane I 123

  Monitor Closely (1)voclosporin, ioflupane I 123. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• iohexol

  Monitor Closely (1)voclosporin, iohexol. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• iopamidol

  Monitor Closely (1)voclosporin, iopamidol. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• iopromide

  Monitor Closely (1)voclosporin, iopromide. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• ioversol

  Monitor Closely (1)voclosporin, ioversol. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• ioxilan

  Monitor Closely (1)voclosporin, ioxilan. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• irbesartan

  Monitor Closely (2)voclosporin and irbesartan both increase serum potassium. Use Caution/Monitor.
  
  voclosporin, irbesartan. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• isoflurane

  Serious - Use Alternative (1)isoflurane and voclosporin both increase QTc interval. Avoid or Use Alternate Drug.

• isoniazid

  Contraindicated (1)isoniazid will increase the level or effect of voclosporin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated.

• isradipine

  Monitor Closely (1)voclosporin, isradipine. Either increases effects of the other by QTc interval. Use Caution/Monitor.

• itraconazole

  Contraindicated (2)itraconazole will increase the level or effect of voclosporin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated.
  
  itraconazole and voclosporin both increase QTc interval. Contraindicated.Monitor Closely (1)voclosporin, itraconazole. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• ivacaftor

  Monitor Closely (1)ivacaftor will increase the level or effect of voclosporin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Reduce voclosporin daily dosage to 15.8 mg PO in AM and 7.9 mg PO in PM.

• ivosidenib

  Serious - Use Alternative (1)ivosidenib will decrease the level or effect of voclosporin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.

• Japanese encephalitis virus vaccine

  Monitor Closely (1)voclosporin decreases effects of Japanese encephalitis virus vaccine by immunosuppressive effects; risk of infection. Modify Therapy/Monitor Closely. Inactivated vaccines noted to be safe for administration may not be sufficiently immunogenic during treatment.

• kanamycin

  Monitor Closely (1)voclosporin, kanamycin. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• ketoconazole

  Contraindicated (1)ketoconazole will increase the level or effect of voclosporin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated.Monitor Closely (1)voclosporin, ketoconazole. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• ketoprofen

  Monitor Closely (1)voclosporin, ketoprofen. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• ketorolac

  Monitor Closely (1)voclosporin, ketorolac. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• ketorolac intranasal

  Monitor Closely (1)voclosporin, ketorolac intranasal. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• lapatinib

  Monitor Closely (2)voclosporin, lapatinib. Either increases effects of the other by QTc interval. Use Caution/Monitor.
  
  lapatinib will increase the level or effect of voclosporin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Reduce voclosporin daily dosage to 15.8 mg PO in AM and 7.9 mg PO in PM.

• larotrectinib

  Monitor Closely (1)larotrectinib will increase the level or effect of voclosporin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Reduce voclosporin daily dosage to 15.8 mg PO in AM and 7.9 mg PO in PM.

• lefamulin

  Monitor Closely (2)voclosporin, lefamulin. Either increases effects of the other by QTc interval. Use Caution/Monitor.
  
  lefamulin will increase the level or effect of voclosporin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Reduce voclosporin daily dosage to 15.8 mg PO in AM and 7.9 mg PO in PM.

• letermovir

  Monitor Closely (2)letermovir will increase the level or effect of voclosporin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Reduce voclosporin daily dosage to 15.8 mg PO in AM and 7.9 mg PO in PM.
  
  voclosporin, letermovir. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.Minor (1)voclosporin will increase the level or effect of letermovir by Other (see comment). Minor/Significance Unknown. Information suggests voclosporin (an OATP1B1 inhibitor) may increase in the concentration of OATP1B1 substrates is possible. Monitor for adverse reactions of OATP1B1 substrates when coadministered with voclosporin.

• levofloxacin

  Monitor Closely (1)voclosporin, levofloxacin. Either increases effects of the other by QTc interval. Use Caution/Monitor.

• levoketoconazole

  Contraindicated (1)levoketoconazole will increase the level or effect of voclosporin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated.Monitor Closely (1)voclosporin, levoketoconazole. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• lisinopril

  Monitor Closely (2)voclosporin and lisinopril both increase serum potassium. Use Caution/Monitor.
  
  voclosporin, lisinopril. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• lisocabtagene maraleucel

  Serious - Use Alternative (1)voclosporin, lisocabtagene maraleucel. Either increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug.

• lithium

  Monitor Closely (1)lithium and voclosporin both increase QTc interval. Use Caution/Monitor.

• lofexidine

  Monitor Closely (1)voclosporin, lofexidine. Either increases effects of the other by QTc interval. Use Caution/Monitor.

• lonafarnib

  Contraindicated (1)lonafarnib will increase the level or effect of voclosporin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated.

• lopinavir

  Contraindicated (1)lopinavir will increase the level or effect of voclosporin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated.Monitor Closely (1)voclosporin, lopinavir. Either increases effects of the other by QTc interval. Use Caution/Monitor.

• lorlatinib

  Serious - Use Alternative (1)lorlatinib will decrease the level or effect of voclosporin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.

• losartan

  Monitor Closely (2)voclosporin and losartan both increase serum potassium. Use Caution/Monitor.
  
  voclosporin, losartan. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• lovastatin

  Minor (1)voclosporin will increase the level or effect of lovastatin by Other (see comment). Minor/Significance Unknown. Information suggests voclosporin (an OATP1B1 inhibitor) may increase in the concentration of OATP1B1 substrates is possible. Monitor for adverse reactions of OATP1B1 substrates when coadministered with voclosporin.

• lumacaftor/ivacaftor

  Serious - Use Alternative (1)lumacaftor/ivacaftor will decrease the level or effect of voclosporin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.

• mannitol

  Monitor Closely (1)voclosporin, mannitol. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• maprotiline

  Monitor Closely (1)voclosporin, maprotiline. Either increases effects of the other by QTc interval. Use Caution/Monitor.

• maribavir

  Monitor Closely (1)voclosporin, maribavir. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• measles (rubeola) vaccine

  Serious - Use Alternative (1)voclosporin decreases effects of measles (rubeola) vaccine by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Immunosuppressants also increase risk of infection with concomitant live vaccines. Avoid live vaccines for at least 3 months after immunosuppressants.

• measles mumps and rubella vaccine, live

  Serious - Use Alternative (1)voclosporin decreases effects of measles mumps and rubella vaccine, live by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Immunosuppressants also increase risk of infection with concomitant live vaccines. Avoid live vaccines for at least 3 months after immunosuppressants.

• measles, mumps, rubella and varicella vaccine, live

  Serious - Use Alternative (1)voclosporin decreases effects of measles, mumps, rubella and varicella vaccine, live by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Immunosuppressants also increase risk of infection with concomitant live vaccines. Avoid live vaccines for at least 3 months after immunosuppressants.

• meclofenamate

  Monitor Closely (1)voclosporin, meclofenamate. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• mefenamic acid

  Monitor Closely (1)voclosporin, mefenamic acid. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• mefloquine

  Monitor Closely (1)voclosporin, mefloquine. Either increases effects of the other by QTc interval. Use Caution/Monitor.

• meloxicam

  Monitor Closely (1)voclosporin, meloxicam. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• melphalan

  Monitor Closely (1)voclosporin, melphalan. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• meningococcal A C Y and W polysaccharide tetanus toxoid conjugate vaccine

  Monitor Closely (1)voclosporin decreases effects of meningococcal A C Y and W polysaccharide tetanus toxoid conjugate vaccine by immunosuppressive effects; risk of infection. Modify Therapy/Monitor Closely. Inactivated vaccines noted to be safe for administration may not be sufficiently immunogenic during treatment.

• meningococcal A C Y and W-135 diphtheria conjugate vaccine

  Monitor Closely (1)voclosporin decreases effects of meningococcal A C Y and W-135 diphtheria conjugate vaccine by immunosuppressive effects; risk of infection. Modify Therapy/Monitor Closely. Inactivated vaccines noted to be safe for administration may not be sufficiently immunogenic during treatment.

• meningococcal A C Y and W-135 polysaccharide vaccine combined

  Monitor Closely (1)voclosporin decreases effects of meningococcal A C Y and W-135 polysaccharide vaccine combined by immunosuppressive effects; risk of infection. Modify Therapy/Monitor Closely. Inactivated vaccines noted to be safe for administration may not be sufficiently immunogenic during treatment.

• meningococcal C and Y/haemophilus influenza type B vaccine

  Monitor Closely (1)voclosporin decreases effects of meningococcal C and Y/haemophilus influenza type B vaccine by immunosuppressive effects; risk of infection. Modify Therapy/Monitor Closely. Inactivated vaccines noted to be safe for administration may not be sufficiently immunogenic during treatment.

• meningococcal group B vaccine

  Monitor Closely (1)voclosporin decreases effects of meningococcal group B vaccine by immunosuppressive effects; risk of infection. Modify Therapy/Monitor Closely. Inactivated vaccines noted to be safe for administration may not be sufficiently immunogenic during treatment.

• mesalamine

  Monitor Closely (1)voclosporin, mesalamine. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• mesalamine rectal

  Monitor Closely (1)voclosporin, mesalamine rectal. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• methadone

  Monitor Closely (1)voclosporin, methadone. Either increases effects of the other by QTc interval. Use Caution/Monitor.

• methotrexate

  Monitor Closely (1)voclosporin, methotrexate. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.Minor (1)voclosporin will increase the level or effect of methotrexate by Other (see comment). Minor/Significance Unknown. Information suggests voclosporin (an OATP1B1 inhibitor) may increase in the concentration of OATP1B1 substrates is possible. Monitor for adverse reactions of OATP1B1 substrates when coadministered with voclosporin.

• metronidazole

  Monitor Closely (1)metronidazole will increase the level or effect of voclosporin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Reduce voclosporin daily dosage to 15.8 mg PO in AM and 7.9 mg PO in PM.

• micafungin

  Monitor Closely (1)voclosporin, micafungin. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• mifepristone

  Contraindicated (1)mifepristone will increase the level or effect of voclosporin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated.Monitor Closely (1)voclosporin, mifepristone. Either increases effects of the other by QTc interval. Use Caution/Monitor.

• mirtazapine

  Monitor Closely (1)mirtazapine and voclosporin both increase QTc interval. Use Caution/Monitor.

• mitotane

  Serious - Use Alternative (1)mitotane will decrease the level or effect of voclosporin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.

• moexipril

  Monitor Closely (2)voclosporin and moexipril both increase serum potassium. Use Caution/Monitor.
  
  voclosporin, moexipril. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• moxifloxacin

  Monitor Closely (1)voclosporin, moxifloxacin. Either increases effects of the other by QTc interval. Use Caution/Monitor.

• nabumetone

  Monitor Closely (1)voclosporin, nabumetone. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• nafcillin

  Serious - Use Alternative (1)nafcillin will decrease the level or effect of voclosporin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.

• naproxen

  Monitor Closely (1)voclosporin, naproxen. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• nefazodone

  Contraindicated (1)nefazodone will increase the level or effect of voclosporin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated.

• nelfinavir

  Contraindicated (1)nelfinavir will increase the level or effect of voclosporin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated.

• neomycin PO

  Monitor Closely (1)voclosporin, neomycin PO. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• netupitant/palonosetron

  Monitor Closely (1)netupitant/palonosetron will increase the level or effect of voclosporin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Reduce voclosporin daily dosage to 15.8 mg PO in AM and 7.9 mg PO in PM.

• nilotinib

  Monitor Closely (1)voclosporin, nilotinib. Either increases effects of the other by QTc interval. Use Caution/Monitor.

• nirmatrelvir/ritonavir

  Contraindicated (1)nirmatrelvir/ritonavir will increase the level or effect of voclosporin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Nirmatrelvir/ritonavir is contraindicated with drugs that are highly dependent on CYP3A for clearance and for which elevated concentrations are associated with serious and/or life-threatening reactions. May increase risk of acute and/or chronic nephrotoxicity associated with voclosporin.

• nortriptyline

  Monitor Closely (1)voclosporin, nortriptyline. Either increases effects of the other by QTc interval. Use Caution/Monitor.

• nystatin

  Monitor Closely (1)voclosporin, nystatin. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• octreotide

  Monitor Closely (1)voclosporin, octreotide. Either increases effects of the other by QTc interval. Use Caution/Monitor.

• ofloxacin

  Monitor Closely (1)voclosporin, ofloxacin. Either increases effects of the other by QTc interval. Use Caution/Monitor.

• olanzapine

  Monitor Closely (1)voclosporin, olanzapine. Either increases effects of the other by QTc interval. Use Caution/Monitor.

• olmesartan

  Monitor Closely (2)voclosporin and olmesartan both increase serum potassium. Use Caution/Monitor.
  
  voclosporin, olmesartan. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.Minor (1)voclosporin will increase the level or effect of olmesartan by Other (see comment). Minor/Significance Unknown. Information suggests voclosporin (an OATP1B1 inhibitor) may increase in the concentration of OATP1B1 substrates is possible. Monitor for adverse reactions of OATP1B1 substrates when coadministered with voclosporin.

• olsalazine

  Monitor Closely (1)voclosporin, olsalazine. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• ombitasvir/paritaprevir/ritonavir

  Minor (1)voclosporin will increase the level or effect of ombitasvir/paritaprevir/ritonavir by Other (see comment). Minor/Significance Unknown. Information suggests voclosporin (an OATP1B1 inhibitor) may increase in the concentration of OATP1B1 substrates is possible. Monitor for adverse reactions of OATP1B1 substrates when coadministered with voclosporin.

• ombitasvir/paritaprevir/ritonavir & dasabuvir (DSC)

  Minor (1)voclosporin will increase the level or effect of ombitasvir/paritaprevir/ritonavir & dasabuvir (DSC) by Other (see comment). Minor/Significance Unknown. Information suggests voclosporin (an OATP1B1 inhibitor) may increase in the concentration of OATP1B1 substrates is possible. Monitor for adverse reactions of OATP1B1 substrates when coadministered with voclosporin.

• ondansetron

  Monitor Closely (1)voclosporin, ondansetron. Either increases effects of the other by QTc interval. Use Caution/Monitor.

• osilodrostat

  Monitor Closely (1)voclosporin, osilodrostat. Either increases effects of the other by QTc interval. Use Caution/Monitor.

• osimertinib

  Monitor Closely (1)voclosporin, osimertinib. Either increases effects of the other by QTc interval. Use Caution/Monitor.

• oteseconazole

  Monitor Closely (1)voclosporin, oteseconazole. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• oxaliplatin

  Serious - Use Alternative (1)oxaliplatin and voclosporin both increase QTc interval. Avoid or Use Alternate Drug.

• oxaprozin

  Monitor Closely (1)voclosporin, oxaprozin. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• ozanimod

  Monitor Closely (1)voclosporin, ozanimod. Either increases effects of the other by QTc interval. Use Caution/Monitor.

• paliperidone

  Monitor Closely (1)voclosporin, paliperidone. Either increases effects of the other by QTc interval. Use Caution/Monitor.

• panobinostat

  Monitor Closely (1)voclosporin, panobinostat. Either increases effects of the other by QTc interval. Use Caution/Monitor.

• pasireotide

  Monitor Closely (1)voclosporin, pasireotide. Either increases effects of the other by QTc interval. Use Caution/Monitor.

• pazopanib

  Monitor Closely (1)voclosporin, pazopanib. Either increases effects of the other by QTc interval. Use Caution/Monitor.

• pentamidine

  Monitor Closely (3)voclosporin and pentamidine both increase serum potassium. Use Caution/Monitor.
  
  voclosporin, pentamidine. Either increases effects of the other by QTc interval. Use Caution/Monitor.
  
  voclosporin, pentamidine. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• pentobarbital

  Serious - Use Alternative (1)pentobarbital will decrease the level or effect of voclosporin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.

• perindopril

  Monitor Closely (2)voclosporin and perindopril both increase serum potassium. Use Caution/Monitor.
  
  voclosporin, perindopril. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• pexidartinib

  Serious - Use Alternative (1)pexidartinib will decrease the level or effect of voclosporin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.

• phenobarbital

  Serious - Use Alternative (1)phenobarbital will decrease the level or effect of voclosporin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.

• phenytoin

  Serious - Use Alternative (1)phenytoin will decrease the level or effect of voclosporin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.

• pimavanserin

  Monitor Closely (1)voclosporin, pimavanserin. Either increases effects of the other by QTc interval. Use Caution/Monitor.

• pimozide

  Monitor Closely (1)voclosporin, pimozide. Either increases effects of the other by QTc interval. Use Caution/Monitor.

• piroxicam

  Monitor Closely (1)voclosporin, piroxicam. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• pitavastatin

  Minor (1)voclosporin will increase the level or effect of pitavastatin by Other (see comment). Minor/Significance Unknown. Information suggests voclosporin (an OATP1B1 inhibitor) may increase in the concentration of OATP1B1 substrates is possible. Monitor for adverse reactions of OATP1B1 substrates when coadministered with voclosporin.

• pitolisant

  Monitor Closely (1)voclosporin, pitolisant. Either increases effects of the other by QTc interval. Use Caution/Monitor.

• plazomicin

  Monitor Closely (1)voclosporin, plazomicin. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• pneumococcal vaccine 13-valent

  Monitor Closely (1)voclosporin decreases effects of pneumococcal vaccine 13-valent by immunosuppressive effects; risk of infection. Modify Therapy/Monitor Closely. Inactivated vaccines noted to be safe for administration may not be sufficiently immunogenic during treatment.

• pneumococcal vaccine 15-valent

  Monitor Closely (1)voclosporin decreases effects of pneumococcal vaccine 15-valent by immunosuppressive effects; risk of infection. Modify Therapy/Monitor Closely. Inactivated vaccines noted to be safe for administration may not be sufficiently immunogenic during treatment.

• pneumococcal vaccine 20-valent

  Monitor Closely (1)voclosporin decreases effects of pneumococcal vaccine 20-valent by immunosuppressive effects; risk of infection. Modify Therapy/Monitor Closely. Inactivated vaccines noted to be safe for administration may not be sufficiently immunogenic during treatment.

• pneumococcal vaccine heptavalent

  Monitor Closely (1)voclosporin decreases effects of pneumococcal vaccine heptavalent by immunosuppressive effects; risk of infection. Modify Therapy/Monitor Closely. Inactivated vaccines noted to be safe for administration may not be sufficiently immunogenic during treatment.

• pneumococcal vaccine polyvalent

  Monitor Closely (1)voclosporin decreases effects of pneumococcal vaccine polyvalent by immunosuppressive effects; risk of infection. Modify Therapy/Monitor Closely. Inactivated vaccines noted to be safe for administration may not be sufficiently immunogenic during treatment.

• poliovirus vaccine inactivated

  Monitor Closely (1)voclosporin decreases effects of poliovirus vaccine inactivated by immunosuppressive effects; risk of infection. Modify Therapy/Monitor Closely. Inactivated vaccines noted to be safe for administration may not be sufficiently immunogenic during treatment.

• poliovirus vaccine live oral trivalent

  Serious - Use Alternative (1)voclosporin decreases effects of poliovirus vaccine live oral trivalent by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Immunosuppressants also increase risk of infection with concomitant live vaccines. Avoid live vaccines for at least 3 months after immunosuppressants.

• polymyxin B

  Monitor Closely (1)voclosporin, polymyxin B. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• posaconazole

  Contraindicated (1)posaconazole will increase the level or effect of voclosporin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated.Monitor Closely (2)voclosporin, posaconazole. Either increases effects of the other by QTc interval. Use Caution/Monitor.
  
  voclosporin, posaconazole. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• potassium acid phosphate

  Monitor Closely (1)voclosporin and potassium acid phosphate both increase serum potassium. Use Caution/Monitor.

• potassium chloride

  Monitor Closely (1)voclosporin and potassium chloride both increase serum potassium. Use Caution/Monitor.

• potassium citrate

  Monitor Closely (1)voclosporin and potassium citrate both increase serum potassium. Use Caution/Monitor.

• potassium citrate/citric acid

  Monitor Closely (1)voclosporin and potassium citrate/citric acid both increase serum potassium. Use Caution/Monitor.

• potassium phosphates, IV

  Monitor Closely (1)voclosporin and potassium phosphates, IV both increase serum potassium. Use Caution/Monitor.

• pravastatin

  Minor (1)voclosporin will increase the level or effect of pravastatin by Other (see comment). Minor/Significance Unknown. Information suggests voclosporin (an OATP1B1 inhibitor) may increase in the concentration of OATP1B1 substrates is possible. Monitor for adverse reactions of OATP1B1 substrates when coadministered with voclosporin.

• primaquine

  Monitor Closely (1)primaquine and voclosporin both increase QTc interval. Use Caution/Monitor.

• primidone

  Serious - Use Alternative (1)primidone will decrease the level or effect of voclosporin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.

• procainamide

  Monitor Closely (1)voclosporin, procainamide. Either increases effects of the other by QTc interval. Use Caution/Monitor.

• protriptyline

  Monitor Closely (1)voclosporin, protriptyline. Either increases effects of the other by QTc interval. Use Caution/Monitor.

• quetiapine

  Monitor Closely (1)voclosporin, quetiapine. Either increases effects of the other by QTc interval. Use Caution/Monitor.

• quinapril

  Monitor Closely (2)voclosporin and quinapril both increase serum potassium. Use Caution/Monitor.
  
  voclosporin, quinapril. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• quinidine

  Monitor Closely (1)voclosporin, quinidine. Either increases effects of the other by QTc interval. Use Caution/Monitor.

• quinine

  Monitor Closely (1)voclosporin, quinine. Either increases effects of the other by QTc interval. Use Caution/Monitor.

• quinupristin/dalfopristin

  Minor (1)quinupristin/dalfopristin will increase the level or effect of voclosporin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown. Reduce voclosporin daily dosage to 15.8 mg PO in AM and 7.9 mg PO in PM.

• rabies vaccine

  Monitor Closely (1)voclosporin decreases effects of rabies vaccine by immunosuppressive effects; risk of infection. Modify Therapy/Monitor Closely. Inactivated vaccines noted to be safe for administration may not be sufficiently immunogenic during treatment.

• rabies vaccine chick embryo cell derived

  Monitor Closely (1)voclosporin decreases effects of rabies vaccine chick embryo cell derived by immunosuppressive effects; risk of infection. Modify Therapy/Monitor Closely. Inactivated vaccines noted to be safe for administration may not be sufficiently immunogenic during treatment.

• ramipril

  Monitor Closely (2)voclosporin and ramipril both increase serum potassium. Use Caution/Monitor.
  
  voclosporin, ramipril. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• ranolazine

  Monitor Closely (1)voclosporin, ranolazine. Either increases effects of the other by QTc interval. Use Caution/Monitor.

• repaglinide

  Minor (1)voclosporin will increase the level or effect of repaglinide by Other (see comment). Minor/Significance Unknown. Information suggests voclosporin (an OATP1B1 inhibitor) may increase in the concentration of OATP1B1 substrates is possible. Monitor for adverse reactions of OATP1B1 substrates when coadministered with voclosporin.

• ribociclib

  Monitor Closely (2)voclosporin, ribociclib. Either increases effects of the other by QTc interval. Use Caution/Monitor.
  
  ribociclib will increase the level or effect of voclosporin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Reduce voclosporin daily dosage to 15.8 mg PO in AM and 7.9 mg PO in PM.

• rifabutin

  Serious - Use Alternative (1)rifabutin will decrease the level or effect of voclosporin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.

• rifamycin

  Minor (1)voclosporin will increase the level or effect of rifamycin by Other (see comment). Minor/Significance Unknown. Information suggests voclosporin (an OATP1B1 inhibitor) may increase in the concentration of OATP1B1 substrates is possible. Monitor for adverse reactions of OATP1B1 substrates when coadministered with voclosporin.

• rifapentine

  Serious - Use Alternative (1)rifapentine will decrease the level or effect of voclosporin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.

• rilpivirine

  Monitor Closely (1)voclosporin, rilpivirine. Either increases effects of the other by QTc interval. Use Caution/Monitor.

• risedronate

  Monitor Closely (1)voclosporin, risedronate. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• risperidone

  Monitor Closely (1)voclosporin, risperidone. Either increases effects of the other by QTc interval. Use Caution/Monitor.

• ritonavir

  Contraindicated (1)ritonavir will increase the level or effect of voclosporin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated.Monitor Closely (1)voclosporin, ritonavir. Either increases effects of the other by QTc interval. Use Caution/Monitor.

• romidepsin

  Monitor Closely (1)voclosporin, romidepsin. Either increases effects of the other by QTc interval. Use Caution/Monitor.

• rosuvastatin

  Minor (1)voclosporin will increase the level or effect of rosuvastatin by Other (see comment). Minor/Significance Unknown. Information suggests voclosporin (an OATP1B1 inhibitor) may increase in the concentration of OATP1B1 substrates is possible. Monitor for adverse reactions of OATP1B1 substrates when coadministered with voclosporin.

• rotavirus oral vaccine, live

  Serious - Use Alternative (1)voclosporin decreases effects of rotavirus oral vaccine, live by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Immunosuppressants also increase risk of infection with concomitant live vaccines. Avoid live vaccines for at least 3 months after immunosuppressants.

• rubella vaccine

  Serious - Use Alternative (1)voclosporin decreases effects of rubella vaccine by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Immunosuppressants also increase risk of infection with concomitant live vaccines. Avoid live vaccines for at least 3 months after immunosuppressants.

• rucaparib

  Contraindicated (1)rucaparib will increase the level or effect of voclosporin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated.

• sacubitril/valsartan

  Monitor Closely (2)voclosporin and sacubitril/valsartan both increase serum potassium. Use Caution/Monitor.
  
  voclosporin, sacubitril/valsartan. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• salsalate

  Monitor Closely (1)voclosporin, salsalate. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• saquinavir

  Contraindicated (1)saquinavir will increase the level or effect of voclosporin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated.Monitor Closely (1)voclosporin, saquinavir. Either increases effects of the other by QTc interval. Use Caution/Monitor.

• SARS-CoV-2 vaccine, inactivated

  Monitor Closely (1)voclosporin decreases effects of SARS-CoV-2 vaccine, inactivated by immunosuppressive effects; risk of infection. Modify Therapy/Monitor Closely. Inactivated vaccines noted to be safe for administration may not be sufficiently immunogenic during treatment.

• schisandra

  Monitor Closely (1)schisandra will increase the level or effect of voclosporin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Reduce voclosporin daily dosage to 15.8 mg PO in AM and 7.9 mg PO in PM.

• secobarbital

  Serious - Use Alternative (1)secobarbital will decrease the level or effect of voclosporin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.

• selpercatinib

  Monitor Closely (1)voclosporin, selpercatinib. Either increases effects of the other by QTc interval. Use Caution/Monitor.

• sertraline

  Monitor Closely (2)voclosporin, sertraline. Either increases effects of the other by QTc interval. Use Caution/Monitor.
  
  sertraline will increase the level or effect of voclosporin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Reduce voclosporin daily dosage to 15.8 mg PO in AM and 7.9 mg PO in PM.

• sevoflurane

  Serious - Use Alternative (1)sevoflurane and voclosporin both increase QTc interval. Avoid or Use Alternate Drug.

• simvastatin

  Minor (1)voclosporin will increase the level or effect of simvastatin by Other (see comment). Minor/Significance Unknown. Information suggests voclosporin (an OATP1B1 inhibitor) may increase in the concentration of OATP1B1 substrates is possible. Monitor for adverse reactions of OATP1B1 substrates when coadministered with voclosporin.

• siponimod

  Serious - Use Alternative (1)siponimod and voclosporin both increase QTc interval. Avoid or Use Alternate Drug.

• sirolimus

  Monitor Closely (1)voclosporin will increase the level or effect of sirolimus by P-glycoprotein (MDR1) efflux transporter. Modify Therapy/Monitor Closely. Coadministration of voclosporin (a P-gp inhibitor) increases exposure and risk of adverse reactions of P-gp substrates. For certain P-gp substrates with a narrow therapeutic window, refer to prescribing information of these substrates for dosage modifications, if needed.

• smallpox (vaccinia) and monkeypox vaccine, live, nonreplicating

  Serious - Use Alternative (2)voclosporin decreases effects of smallpox (vaccinia) vaccine, attenuated by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Immunosuppressants also increase risk of infection with concomitant live vaccines. Avoid live vaccines for at least 3 months after immunosuppressants.
  
  voclosporin decreases effects of smallpox (vaccinia) vaccine, attenuated by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Immunosuppressants also increase risk of infection with concomitant live vaccines. Avoid live vaccines for at least 3 months after immunosuppressants.

• smallpox (vaccinia) vaccine, live

  Serious - Use Alternative (1)voclosporin decreases effects of smallpox (vaccinia) vaccine, live by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Immunosuppressants also increase risk of infection with concomitant live vaccines. Avoid live vaccines for at least 3 months after immunosuppressants.

• sodium phosphates, IV

  Monitor Closely (1)voclosporin, sodium phosphates, IV. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• solifenacin

  Monitor Closely (1)voclosporin, solifenacin. Either increases effects of the other by QTc interval. Use Caution/Monitor.

• sorafenib

  Monitor Closely (1)voclosporin, sorafenib. Either increases effects of the other by QTc interval. Use Caution/Monitor.

• sotalol

  Monitor Closely (1)voclosporin, sotalol. Either increases effects of the other by QTc interval. Use Caution/Monitor.

• spironolactone

  Monitor Closely (1)voclosporin and spironolactone both increase serum potassium. Use Caution/Monitor.

• St John's Wort

  Serious - Use Alternative (1)St John's Wort will decrease the level or effect of voclosporin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.

• stiripentol

  Contraindicated (1)stiripentol will increase the level or effect of voclosporin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated.

• streptomycin

  Monitor Closely (1)voclosporin, streptomycin. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• streptozocin

  Monitor Closely (1)voclosporin, streptozocin. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• succinylcholine

  Monitor Closely (1)voclosporin and succinylcholine both increase serum potassium. Use Caution/Monitor.

• sulfadiazine

  Monitor Closely (1)voclosporin, sulfadiazine. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• sulfasalazine

  Monitor Closely (1)voclosporin, sulfasalazine. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• sulfisoxazole

  Monitor Closely (1)voclosporin, sulfisoxazole. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• sulindac

  Monitor Closely (1)voclosporin, sulindac. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• sunitinib

  Monitor Closely (1)voclosporin, sunitinib. Either increases effects of the other by QTc interval. Use Caution/Monitor.

• tacrolimus

  Monitor Closely (2)voclosporin and tacrolimus both increase serum potassium. Use Caution/Monitor.
  
  voclosporin, tacrolimus. Either increases effects of the other by QTc interval. Use Caution/Monitor.

• telavancin

  Monitor Closely (1)voclosporin, telavancin. Either increases effects of the other by QTc interval. Use Caution/Monitor.

• telmisartan

  Monitor Closely (2)voclosporin and telmisartan both increase serum potassium. Use Caution/Monitor.
  
  voclosporin, telmisartan. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• telotristat ethyl

  Serious - Use Alternative (1)telotristat ethyl will decrease the level or effect of voclosporin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.

• temsirolimus

  Monitor Closely (1)voclosporin will increase the level or effect of temsirolimus by P-glycoprotein (MDR1) efflux transporter. Modify Therapy/Monitor Closely. Coadministration of voclosporin (a P-gp inhibitor) increases exposure and risk of adverse reactions of P-gp substrates. For certain P-gp substrates with a narrow therapeutic window, refer to prescribing information of these substrates for dosage modifications, if needed.

• tenofovir AF

  Monitor Closely (1)voclosporin, tenofovir AF. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• tenofovir DF

  Monitor Closely (1)voclosporin, tenofovir DF. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• terbinafine

  Monitor Closely (1)voclosporin, terbinafine. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• tetanus toxoid adsorbed or fluid

  Monitor Closely (1)voclosporin decreases effects of tetanus toxoid adsorbed or fluid by immunosuppressive effects; risk of infection. Modify Therapy/Monitor Closely. Inactivated vaccines noted to be safe for administration may not be sufficiently immunogenic during treatment.

• tetrabenazine

  Monitor Closely (1)voclosporin, tetrabenazine. Either increases effects of the other by QTc interval. Use Caution/Monitor.

• tetracycline

  Monitor Closely (1)tetracycline will increase the level or effect of voclosporin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Reduce voclosporin daily dosage to 15.8 mg PO in AM and 7.9 mg PO in PM.

• thioridazine

  Monitor Closely (1)voclosporin, thioridazine. Either increases effects of the other by QTc interval. Use Caution/Monitor.

• thiothixene

  Monitor Closely (1)voclosporin, thiothixene. Either increases effects of the other by QTc interval. Use Caution/Monitor.

• tick-borne encephalitis vaccine

  Monitor Closely (1)voclosporin decreases effects of tick-borne encephalitis vaccine by immunosuppressive effects; risk of infection. Modify Therapy/Monitor Closely. Inactivated vaccines noted to be safe for administration may not be sufficiently immunogenic during treatment.

• tiludronate

  Monitor Closely (1)voclosporin, tiludronate. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• tipranavir

  Contraindicated (1)tipranavir will increase the level or effect of voclosporin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated.

• tisagenlecleucel

  Serious - Use Alternative (1)voclosporin, tisagenlecleucel. Either increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug.

• tobramycin

  Monitor Closely (1)voclosporin, tobramycin. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• tobramycin inhaled

  Monitor Closely (1)voclosporin, tobramycin inhaled. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• tolmetin

  Monitor Closely (1)voclosporin, tolmetin. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• trandolapril

  Monitor Closely (2)voclosporin and trandolapril both increase serum potassium. Use Caution/Monitor.
  
  voclosporin, trandolapril. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• triamterene

  Monitor Closely (1)voclosporin and triamterene both increase serum potassium. Use Caution/Monitor.

• trimethoprim

  Monitor Closely (1)voclosporin and trimethoprim both decrease serum potassium. Use Caution/Monitor.

• trimipramine

  Monitor Closely (1)voclosporin, trimipramine. Either increases effects of the other by QTc interval. Use Caution/Monitor.

• troglitazone

  Minor (1)voclosporin will increase the level or effect of troglitazone by Other (see comment). Minor/Significance Unknown. Information suggests voclosporin (an OATP1B1 inhibitor) may increase in the concentration of OATP1B1 substrates is possible. Monitor for adverse reactions of OATP1B1 substrates when coadministered with voclosporin.

• typhoid polysaccharide vaccine

  Serious - Use Alternative (1)voclosporin decreases effects of typhoid polysaccharide vaccine by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Immunosuppressants also increase risk of infection with concomitant live vaccines. Avoid live vaccines for at least 3 months after immunosuppressants.

• typhoid vaccine live

  Serious - Use Alternative (1)voclosporin decreases effects of typhoid vaccine live by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Immunosuppressants also increase risk of infection with concomitant live vaccines. Avoid live vaccines for at least 3 months after immunosuppressants.

• ublituximab

  Monitor Closely (1)ublituximab and voclosporin both increase immunosuppressive effects; risk of infection. Modify Therapy/Monitor Closely. Owing to potential additive immunosuppressive effects, consider duration of effect and mechanism of action of these therapies if coadministered

• umeclidinium bromide/vilanterol inhaled

  Monitor Closely (1)voclosporin, umeclidinium bromide/vilanterol inhaled. Either increases effects of the other by QTc interval. Use Caution/Monitor.

• upadacitinib

  Serious - Use Alternative (1)voclosporin, upadacitinib. Either increases effects of the other by immunosuppressive effects; risk of infection. Contraindicated.

• valganciclovir

  Monitor Closely (1)voclosporin, valganciclovir. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• valsartan

  Monitor Closely (2)voclosporin and valsartan both increase serum potassium. Use Caution/Monitor.
  
  voclosporin, valsartan. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.Minor (1)voclosporin will increase the level or effect of valsartan by Other (see comment). Minor/Significance Unknown. Information suggests voclosporin (an OATP1B1 inhibitor) may increase in the concentration of OATP1B1 substrates is possible. Monitor for adverse reactions of OATP1B1 substrates when coadministered with voclosporin.

• vancomycin

  Monitor Closely (1)voclosporin, vancomycin. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• vandetanib

  Monitor Closely (1)voclosporin, vandetanib. Either increases effects of the other by QTc interval. Use Caution/Monitor.

• vardenafil

  Monitor Closely (1)voclosporin, vardenafil. Either increases effects of the other by QTc interval. Use Caution/Monitor.

• varicella virus vaccine live

  Serious - Use Alternative (1)voclosporin decreases effects of varicella virus vaccine live by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Immunosuppressants also increase risk of infection with concomitant live vaccines. Avoid live vaccines for at least 3 months after immunosuppressants.

• vemurafenib

  Monitor Closely (1)voclosporin, vemurafenib. Either increases effects of the other by QTc interval. Use Caution/Monitor.

• verapamil

  Monitor Closely (1)verapamil will increase the level or effect of voclosporin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Reduce voclosporin daily dosage to 15.8 mg PO in AM and 7.9 mg PO in PM.

• voriconazole

  Contraindicated (1)voriconazole will increase the level or effect of voclosporin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated.Monitor Closely (2)voclosporin, voriconazole. Either increases effects of the other by QTc interval. Use Caution/Monitor.
  
  voclosporin, voriconazole. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• vorinostat

  Monitor Closely (1)voclosporin, vorinostat. Either increases effects of the other by QTc interval. Use Caution/Monitor.

• voxelotor

  Monitor Closely (1)voxelotor will increase the level or effect of voclosporin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Reduce voclosporin daily dosage to 15.8 mg PO in AM and 7.9 mg PO in PM.

• voxilaprevir

  Minor (1)voclosporin will increase the level or effect of voxilaprevir by Other (see comment). Minor/Significance Unknown. Information suggests voclosporin (an OATP1B1 inhibitor) may increase in the concentration of OATP1B1 substrates is possible. Monitor for adverse reactions of OATP1B1 substrates when coadministered with voclosporin.

• yellow fever vaccine

  Serious - Use Alternative (1)voclosporin decreases effects of yellow fever vaccine by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Immunosuppressants also increase risk of infection with concomitant live vaccines. Avoid live vaccines for at least 3 months after immunosuppressants.

• ziprasidone

  Monitor Closely (1)voclosporin, ziprasidone. Either increases effects of the other by QTc interval. Use Caution/Monitor.

• zoledronic acid

  Monitor Closely (1)voclosporin, zoledronic acid. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity.

• zoster vaccine live

  Serious - Use Alternative (1)voclosporin decreases effects of zoster vaccine live by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Immunosuppressants also increase risk of infection with concomitant live vaccines. Avoid live vaccines for at least 3 months after immunosuppressants.

• zoster vaccine recombinant

  Monitor Closely (1)voclosporin decreases effects of zoster vaccine recombinant by immunosuppressive effects; risk of infection. Modify Therapy/Monitor Closely. Inactivated vaccines noted to be safe for administration may not be sufficiently immunogenic during treatment.